Formulation and evaluation of polymeric micelles for improved oral delivery of tenofovir disoproxil fumarate and zidovudine using poly-lactic-co-glycolic acid nanoparticles by Tenghe, Lovette Asobo
 
 
FORMULATION AND EVALUATION OF POLYMERIC MICELLES FOR 
IMPROVED ORAL DELIVERY OF TENOFOVIR DISOPROXIL FUMARATE AND 
ZIDOVUDINE USING POLY-LACTIC-CO-GLYCOLIC ACID NANOPARTICLES 
 
By 
Lovette Asobo Tenghe  
 
 
 
A thesis submitted in fulfilment of the requirements for the degree of 
Magister Pharmaceuticiae 
 
Discipline of Pharmaceutics, School of Pharmacy, 
Faculty of Natural Sciences, 
University of the Western Cape, Bellville, South Africa 
 
Supervisor: Dr Halima Samsodien 
 
Co-supervisor: Dr Oluchi Mbamalu 
 
December 2018
 
http://etd.uwc.ac.za/
Abstract  
 
i 
 
ABSTRACT 
Background: Tenofovir disoproxil fumarate (TDF) and Zidovudine (AZT) are both 
nucleotide and nucleoside analogue reverse transcriptase inhibitors (NtRTIs and 
NRTIs), respectively. They are used for the management and prevention of the 
Human Immunodeficiency Virus (HIV) infection. These drugs are faced with oral 
delivery challenges such as low intestinal permeability and extensive first pass liver 
metabolism for TDF and AZT, respectively. Their use may also be limited by dose-
dependent adverse effects, which may result in treatment failure when patients 
become non-compliant and non-adherent to their prescribed antiretroviral (ARV) 
regimen. Non-compliance and non-adherence to ARV regimen may lead to drug 
resistance and a need for change in regimen, which can be very expensive, not 
only financially but in terms of morbidity and mortality. To solve such issues, a new 
drug can be formulated, or an existing drug can be modified. The development and 
formulation of a new drug is time consuming and expensive, especially with no 
available data and a high probability of failure. Modifying existing drugs is a 
cheaper, less time-consuming option with lower probability of failure. Such 
modification can be achieved via non-covalent interactions using various methods 
such as preparation of nano-particulates with polymeric micelles (a non-covalent 
interaction). Polymeric micelles offer a variety of polymers to choose from for drug 
modification purposes.  
Purpose: The aim of this study was to formulate polymeric nanoparticles of TDF 
and AZT using different ratios of poly-lactic-co-glycolic acid (PLGA), characterize 
the formulated nanoparticles (using the following analyses: particle size, zeta 
potential, encapsulation efficiency, hot stage microscopy, thermogravimetric 
analysis, differential scanning calorimetry, Fourier transform infrared spectroscopy 
and scanning electron microscopy), analyze for stability during storage (2-8˚C) and 
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determine the release rate of the active pharmaceutical ingredients in the 
formulated nanoparticles.  
Methods: Nanoparticles were prepared using a modified version of the double 
emulsion (water-in-oil-in-water) solvent evaporation and diffusion method. Two 
ratios of PLGA (50:50 and 85:15) were used to prepare four formulations (two each 
of TDF and AZT). Thereafter, the physicochemical and pharmaceutical properties 
of the formulations were assessed by characterizing the nanoparticles for particle 
size, zeta potential, polydispersity index, percentage yield, release profile and 
particle morphology, using the suggested analytical techniques. 
Results: For TDF-PLGA 85:15, TDF-PLGA 50:50, AZT-PLGA 85:15 and AZT-
PLGA 50:50, nanoparticles of 160.4±1.7 nm,154.3±3.1 nm,127.0±2.32 nm and 
153.2±4.3 nm, respectively, were recovered after washing. The polydispersity index 
(PDI) values were ≤0.418±0.004 after washing, indicating that the formulations 
were monodispersed. The zeta potential of the particles was -5.72±1 mV, -19.1 mV, 
-12.2±0.6 mV and -15.3±0.5 mV for TDF-PLGA 85:15, TDF-PLGA 50:50, AZT-
PLGA 85:15 and AZT-PLGA 50:50 respectively after washing. The highest 
percentage yield was calculated to be 79.14% and the highest encapsulation 
efficiency obtained was 73.82% for AZT-PLGA 50:50, while the particle morphology 
showed spherical nanoparticles with signs of coalescence and aggregation for all 
formulated nanoparticles. The release profiles were biphasic; that is, an initial burst 
which indicated the presence of surface API followed by sustained release. 
Comparing the release profiles of AZT and TDF at pH 1.2 and 7.4, it was indicative 
that more AZT was released at pH 1.2 while more TDF was released at pH 7.4. On 
computing the release data further into various mathematical models, the Weibull 
model was found to be the best fit. The loaded nanoparticles showed an increase 
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in stability after washing; however, they showed signs of gradual decrease in 
stability after 10 days of storage at 2-8°C. 
Conclusions: Relatively small, spherical and smooth nanoparticles were 
formulated. The nanoparticle release profile was indicative of sustained release; 
however, there was no conclusive indication that 48 hours duration was sufficient 
to release all encapsulated drug. Further studies with an increased API or polymer 
ratio in the formulation needs to be performed to determine if the encapsulation 
efficiency can be improved and in-vivo studies are required for a better 
understanding of the API release from formulations as well as its absorption in the 
body. 
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CHAPTER 1: INTRODUCTION 
Chapter 1 introduces the epidemic posed by the Human Immunodeficiency Virus (HIV) 
in South Africa and around the world, specifically the challenges faced with the drugs 
used in managing the epidemic, and some of the methods that may be used to 
attenuate such challenges. 
1.1 HIV Background   
According to the World Health Organization (WHO), since the dawn of the HIV 
epidemic, more than 70 million people have been infected with the HIV virus and about 
35 million people have died from HIV-related infections. At the end of 2016, 36.7 million 
[34.0-39.8 million] people globally were living with HIV, with adults between the ages 
of 15 and 49 years making up about 0.8% [0.7-0.9%] of this population.[1] Sub-Saharan 
Africa accounts for nearly 70% of the total population of people living with HIV 
worldwide; about 1 in 25 adults (4.4%) in the region are living with HIV.[1] With South 
Africa having the highest HIV epidemic profile in the world, an estimated 7 million 
people in the country were living with HIV at the end of 2016, and an estimated total 
of 380 000 new infections were reported, with 180 000 deaths from AIDS-related 
illnesses.[2] Little wonder then that the Antiretroviral Treatment (ART) program in South 
Africa is the largest globally, with about $1.5 billion invested annually from the 
country’s domestic resources to run the HIV and AIDS programs.[3] The need to 
prevent the spread of HIV/AIDS cannot be overemphasized. It accounts for severe 
mortality and morbidity, and has a negative impact on the country’s economy, both in 
the private and public sector. Most people infected fall between the age groups of 20 
and 40 years of age. As such, the epidemic affects the most productive years of the 
infected patient’s life and the workforce of the country, leading to a general reduction 
in the progress of economic development and a decrease in life expectancy. 
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Consequently, the South African government spends a substantial amount in 
supporting AIDS-orphaned children, who face several challenges such as migration to 
relatives, financial stress and food insecurities.[4-5] As aforementioned, the need to 
contain this scourge cannot be over-emphasized. The current therapy with ARVs has 
improved the quality and prolonged the lives of many infected individuals. These drugs 
may however pose delivery challenges, and severe side effect profiles, which may be 
counterproductive to therapeutic success. Such challenges may be overcome by non-
covalent nano-formulation of the drugs with suitable polymers.  
Nano-formulations  
In the pharmaceutical industry, the various forms of nano-formulations available have 
become the focal point of many researchers due to their drug delivery capabilities. 
Nano-formulations have revolutionized cell specific targeting and controlled drug 
release, and can deliver vaccines, conventional drugs, nucleotides and recombinant 
proteins.[6,7] Both hydrophobic and hydrophilic drugs can be encapsulated within 
nanoparticles (NPs), and so a need can be proven for the nano-formulation of almost 
any agent. Modifying plasma exposure levels via sustained release or cell targeting, a 
technique that can be achieved with nano-formulations, can further reduce toxicities 
and adverse effects associated with therapeutic agents. An example of an effective 
therapeutic agent with unacceptable adverse effects and/or toxicities that has been 
reformulated as NPs to reduce these adverse effects is paclitaxel, an approved drug 
for chemotherapy. Paclitaxel has been formulated into albumin-based NPs 
(Abraxane®). Abraxane® has been proven to greatly reduce the adverse effects (such 
as ocular toxicity, hypersensitivity reactions, myelosuppression, peripheral 
neuropathy, nausea, vomiting, fatigue, arthralgia, myalgia and alopecia) associated 
with paclitaxel.[7- 9] 
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NPs can be optimized by shape and size or functionalized with lipid coatings and 
protein to facilitate their cellular uptake, drug release, and ability to cross physiologic 
barriers such as the blood-brain barrier.[10-12] NPs can be further functionalized with 
ligands such as those with immune system modulating effects, concurrently modifying 
the cellular immune response and enhancing intracellular drug delivery. [13] Chitosan 
(CS) has gained attention in the nanomedicine field because it carries a positive 
charge that can be used for cellular and anatomic targeting of NPs.[14] The electrostatic 
interactions between positively charged CS NPs and the negatively charged cell 
surface have been shown to enhance NP uptake[15-20] by using a poly-lactic-co-glycolic 
acid (PLGA) core in conjunction with a CS shell. This has advanced drug delivery and 
further specified drug target sites and degradation rates to achieve a specific 
therapeutic response. Such desirable characteristics can be harnessed for the non-
covalent formulation of Tenofovir disoproxil fumarate (TDF) and Zidovudine (AZT) 
complexes in this study.  
1.2 Tenofovir disoproxil fumarate (TDF) and Zidovudine (AZT)  
TDF and AZT are antiretroviral agents. In South Africa, they form part of the first line 
antiretroviral (ARV) regimen. In patients suffering from renal insufficiency, TDF may 
be replaced with AZT.[21] The optimal delivery of these drugs is limited by the low 
bioavailability of TDF (due to its low permeability), and the short plasma half-life and 
first pass metabolism of AZT (which has resulted in twice daily administration of AZT 
to achieve and maintain effective plasma concentration levels). The disadvantage of 
this is a cumulative high drug dose and dose-dependent adverse effects such as 
neutropenia, hepatotoxicity, myopathy and renal dysfunction.[22] Such adverse effects 
may result in treatment failure when patients become non-compliant and non-adherent 
to their prescribed ARV regimen. The result is often drug resistance; the patient may 
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need a change to another regimen which may be more expensive, not only financially 
but in terms of morbidity and quality of life. Therefore, the field of long-acting, cell-
targeted ARVs has become a major area of research. 
In this growing field of study, the shortcomings of commonly utilized drugs (e.g. ARVs) 
are researched. Shortcomings may be resolved by synthesizing a new drug or 
modifying the existing drugs. Synthesizing a new drug, however is time-consuming 
and expensive. In addition, with little or no existing data available, there is a very high 
risk of product failure. On the other hand, modifying existing drugs will likely be less 
time-consuming and more cost effective, because there is some information about the 
drug already available and there is a relatively low risk of product failure. Modification 
of existing drugs can be achieved by:  
❖ use of polymeric micelles, 
❖ use of hydrates or solvates, 
❖ solvent deposition, 
❖ self-dispersing lipid formulation (SDLF), and 
❖ lipid based delivery systems. 
Polymeric micelle formulation presents a variety of options since there are many 
polymers to choose from. However, the inability to work with all at the same time to 
select the best, poses a limitation. One of the most affordable polymers is poly-(D,L)-
lactic-co-glycolic acid (PLGA); a co-polymer of poly lactic acid (PLA) and poly glycolic 
acid (PGA). It is considered one of the best biomaterials for drug delivery based on its 
design and performance.[20] The toxicities associated with the use of current ARVs 
such as TDF and AZT may be attenuated using co-polymers such as PLGA. PLGA 
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encapsulates the drug in polymeric micelles which are delivered across lipophilic 
barriers, thereby increasing drug absorption (bioavailability, BA) across the intestinal 
mucosa. Formulation with such a co-polymer may result in improved drug 
absorption/bioavailability by improving permeability, a modification which may very 
well work to improve TDF bioavailability. The short plasma half-life and first pass 
metabolism of AZT may also be addressed by co-formulation with appropriate 
polymers. Such co-formulation may avoid first pass effect through an increase in 
lymphatic uptake, resulting in the achievement of higher systemic drug concentrations 
with lower drug doses.[23,24] This may in turn result in reduced incidence of dose-
dependent side effects as well as promote sustainable prescribing.[25,26] 
Hypothesis 
It was hypothesized that, co-formulation of TDF and AZT with PLGA to produce TDF-
PLGA and AZT-PLGA nanoparticles, respectively, would improve absorption and 
reduce the dose of drug required to attain therapeutic concentrations, thereby 
improving bioavailability and reducing the adverse effects associated with the use of 
these APIs when administered orally. 
1.3 OBJECTIVES 
The objectives of this study were:  
❖ to characterize TDF and PLGA (50:50 and 85:15); 
❖ to formulate TDF-PLGA and AZT-PLGA nanoparticles; 
❖ to characterize and compare the physicochemical properties of the formulated 
complexes using various analytical techniques; 
❖ to compare the pharmaceutical properties of both formulations (i.e.: in vitro 
release and stability). 
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Chapter 2 will now follow with a brief literature review on the APIs and poly-lactic-co-
glycolic acid. 
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CHAPTER 2: LITERATURE REVIEW 
Introduction  
This chapter reviews the literature on Tenofovir disoproxil fumarate (TDF), Zidovudine 
(AZT) and poly-lactic-co-glycolic acid (PLGA).  
2.1 TENOFOVIR DISOPROXIL FUMARATE 
 
Figure 2.1: Chemical structure of Tenofovir disoproxil fumarate (TDF) 
Tenofovir disoproxil fumarate (TDF, Figure 2.1) is classified as a nucleotide analogue 
reverse transcriptase inhibitor (NtRTI). It is a highly effective antiretroviral (ARV) drug 
used predominantly in combination with other ARVs for the management and 
prevention of infections by the Human Immunodeficiency Virus (HIV).[1] It is well 
established as a component of ARV combination therapy regimens in the 
management of adults with HIV infection. TDF does not inhibit cytochrome P450 
enzymes, so few drug interactions are expected with drugs metabolized via this 
route.[2]  
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In addition to its use in ARV therapy, TDF is also used for the treatment of hepatitis B 
virus (HBV) infection.[3] A substantial amount of HIV-infected individuals are co-
infected with HBV[4] and are at a risk of developing HBV-associated diseases such as 
hepatocellular carcinoma and cirrhosis.[1] TDF is very effective against HBV, hence its 
continued use as part of the first-line treatment of HIV infected patients, where it serves 
dual purposes.[1,3]  
In terms of physical properties, TDF is a hydrophilic drug, classified as a class III agent 
according to the Biopharmaceutical Classification System (BCS).[5] This implies that it 
has high solubility and low intestinal permeability. The latter may account partially for 
its low bioavailability (BA) (about 25% without food) which can be increased (to about 
40%) with a high fat meal.[5] This improved BA however, may still be considered very 
low. TDF itself is an ester prodrug of tenofovir designed to increase tenofovir’s 
absorption across the intestine. However, this method of drug design to increase 
efficiency to overcome intestinal barriers can be decreased by the rapid esterase-
mediated hydrolysis and P-glycoprotein (P-gp)-related efflux of the drug.[6,7] These 
factors contribute to the drug’s low BA. To address this limitation, a large dose (300 
mg) is usually administered to ensure that the minimum plasma concentration required 
for antiviral activity is attained. Administration of such a large dose may however 
predispose the patient to dose-dependent drug toxicity, a well-known adverse effect 
associated with TDF usage.[8]  
Another limitation to the use of TDF is its nephrotoxic potential. Studies have 
documented TDF as the most common cause of nephrotoxicity in HIV patients being 
referred to nephrologists, accounting for at least 20% of nephrologists’ 
consultations.[9,10] Polyuropolydipsic syndrome has also been associated with TDF use 
within six months of such use, and full resolution of renal dysfunction 
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(polyuropolydipsic syndrome) reported within three weeks of withdrawing TDF.[11] In 
more severe cases of TDF toxicity, patients can develop acute kidney injury, 
osteomalacia, and Fanconi syndrome (characterized by phosphaturia, tubular 
proteinuria, bicarbonate wasting, glycosuria, and amino aciduria, which can lead to 
further complications such as metabolic acidosis).[9,11] The main site of TDF 
nephrotoxicity seems to be the proximal tubule and the epithelia cells of the conducting 
ducts. As TDF is eliminated by renal excretion, dose adjustments are necessary in 
patients with significant renal impairment.  
We hypothesize that co-formulation with a suitable polymer will improve solubility and 
permeability of TDF. With such improved solubility and permeability, therapeutic 
efficacy may be attained with lower drug doses, resulting in less incidence of dose-
dependent drug toxicity.   
Table 2.1: Physicochemical properties of Tenofovir disoproxil fumarate[12] 
Biopharmaceutical classification Class III: high solubility and low permeability 
Molecular formula C23H24N5O14P 
Molecular weight 635.514922 g/mol 
Melting point 114-118 °C 
Solubility (in water) 13.4 mg/ml at 25 ºC 
Appearance White, fine, powder-like crystals 
Log P 1.25 at pH of 6.5 
 
Table 2.2 presents information on the pharmacokinetic and clinical properties of TDF, 
and its legal status in South Africa (schedule 4). As a schedule 4 medicine, it can only 
be obtained with a valid prescription from an authorized prescribing doctor. 
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Table 2.2: Pharmacokinetic and clinical properties of Tenofovir disoproxil fumarate  
Trade Name Viread® (Gilead Sciences Inc.) 
South African legal status Schedule 4 
Bioavailability 25% in fasted state 
Half-life 17 hours 
Route of administration Oral 
Renal excretion 70-80% 
Protein binding <7% 
 
2.1.1 Mechanism of action 
TDF is a prodrug which is hydrolyzed in vivo to tenofovir, which then undergoes 
phosphorylation to tenofovir diphosphate for its antiretroviral effect. Tenofovir 
diphosphate inhibits the enzyme, HIV reverse transcriptase, by competing with the 
substrate, deoxyadenosine 5̍-triphosphate. It therefore acts as a DNA chain terminator 
by preventing DNA chain elongation because it lacks the 3-hydroxyl group required 
for the formation of an ester linkage with the phosphate group of the next nucleotide 
(Figure 2.2).[13] 
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Figure 2.2: Structural representation: of Tenofovir disoproxil fumarate - 
mechanism of action  
2.1.2 Mechanism of TDF associated toxicities 
The kidneys serve as a major route of drug excretion from the body, with several 
interactions, leading eventually to excretion, taking place in the proximal tubules. As 
such, there exists the potential for interactions that could lead to toxicity between TDF 
and other agents in this segment of the nephron.[11] TDF enters the epithelial cells at 
its basolateral pole using the organic transporter.[14,15] It gets into the tubular lumen via 
multidrug resistant proteins (MRP2, MRP3, MRP4).[16-18] The apical transporter 
multidrug resistance-associated protein 4 (MRP4) aids its (i.e., TDF’s) exit from the 
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cells.[19] Evidence suggests that the proximal tubule is enriched with a high density of 
mitochondria; and these organelles are targets of TDF toxicity.[11]  
The intracellular concentrations of TDF can increase as its plasma concentrations 
increase or the apical secretion of TDF is inhibited.[14] This leads to oxidative 
respiratory chain dysfunctions,[19] inhibition of mitochondrial DNA (mtDNA) 
polymerase γ,[20] and depletion of mtDNA.[14,19,21] As such, structural changes to the 
mitochondria are induced in the proximal tubular epithelial cells.[19,22] This leads to 
shortage in the production of ATP, resulting in tubular cells reabsorption of small 
molecules or ions such as uric acid, amino acids, potassium, glucose, β2-microglobulin 
and phosphate. These molecules are secreted abnormally in the urine, a condition 
referred to as the Fanconi syndrome.  
Genetic polymorphism and drug interactions with transporters may also explain why 
TDF might accumulate in the proximal tubular cells of some patients. Another 
contributing factor is the inhibition of the enzyme, DNA polymerase γ, which is 
responsible for the replication of mtDNA.[23] Such inhibition leaves the proximal tubule 
vulnerable because of the mitochondria’s limited ability to anaerobically generate 
ATP.[24] If these mechanisms of TDF toxicity can be attenuated by non-covalent 
polymeric micelle formulation parameters, it would be another advantage obtained 
from the non-covalent formulation of the TDF complexes. 
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2.2 ZIDOVUDINE 
 
Figure 2.3: Chemical structure of Zidovudine 
Zidovudine (also known as azido thymidine, or AZT, Figure 2.3) was the first 
nucleoside analogue reverse transcriptase inhibitor (NRTI) clinically approved by the 
Food and Drug Administration (FDA) for the management of HIV/AIDS. This was in 
March 1987, six years after AIDS was first reported.[25] Generally, AZT is administered 
as an oral dose of 300 mg twice a day, or 1 mg per kilogram over 1 hour every 4 hours 
for intravenous infusions. In South Africa, AZT is used both as a first- and second-line 
agent in Highly Active Antiretroviral Therapy (HAART) regimen. [26] It is also used for 
Post Exposure Prophylaxis (PEP) following exposure of individuals and heath care 
workers to HIV infection, and especially in the Prevention of Mother to Child 
Transmission (PMTCT) of HIV. [27,28]  
 
 
 
 
 
http://etd.uwc.ac.za/
 Chapter 2: Literature review 
18 
 
Table 2.3: Chemical and physical properties of Zidovudine [29] 
Biopharmaceutical 
classification 
Class III: high solubility and low 
permeability  
Molecular formula C10H13N5O4 
Molecular weight 267.24132 g/mol 
Melting point 120-127 °C 
Solubility (in water) 20.1 mg/L (at 25 °C) 
Color White to beige, crystalline solid 
LogP 0.05 
 
AZT is a hydrophilic drug, a class III agent according to the BCS classification. Its 
clinical effectiveness is constrained due to sub-optimal pharmacokinetics viz. 
extensive first pass metabolism, inhibition of mitochondrial machinery, and a short 
plasma half-life (t1/2 = 1 to 2 hours)[24,30-32] (Table 2.4). These lead to a required 
increase in AZT’s dosage and frequency of administration in order to attain and 
maintain therapeutic plasma levels. High doses may result in unwanted side effects 
such as anemia, neutropenia, hepatotoxicity, cardiomyopathy, and myopathy. [24,33] 
HIV patients on AZT have been known to present with hypo-proliferative anemia which 
resolves on drug withdrawal.[34] Such adverse effect may compromise patient 
adherence to therapy. Because these adverse effects may be dose-dependent, a 
reduction in dose may reduce incidents of such adverse effects.[35,36] As proposed for 
TDF, we hypothesize that co-formulation with a suitable polymer will improve solubility 
and permeability of AZT, beyond that currently obtainable. With such improved 
solubility and permeability, therapeutic efficacy may be attained with lower drug (AZT) 
doses, resulting in less incidence of dose-dependent adverse effects. 
As the antiviral effect of AZT is time-dependent,[37] an adequate zero-order delivery 
system is required to maintain activity as well as to avoid dose-induced toxic 
responses.[38-41] For instance, the formulation of iron oxide nanoparticles (PLGA) for 
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the delivery of anticancer agents was proven to attenuate the dose-dependent anti-
proliferative activity in prostate and cancer cells.[42] 
AZT is a substrate of various drug efflux mechanisms that are present in the intestinal 
epithelium, central nervous system (CNS) and immune system. These efflux systems 
are mediated by permeability glycoprotein (P-gp), and adenosine triphosphate (ATP) 
binding cassette of the ABC (transport) protein family.[43] As a result of this efflux, drug 
resistant strains of the virus might develop.[32] This in effect accounts for cases of inter- 
and intra-patient non-linearity and variability observed in the bioavailability of AZT.[44,45]  
Table 2.4 presents information on the pharmacokinetic and clinical properties of AZT, 
and its legal status in South Africa (schedule 4). As a schedule 4 medicine, it can only 
be obtained with a valid prescription from an authorized prescribing doctor.  
Table 2.4: Pharmacokinetic and clinical properties of Zidovudine 
Trade Name Aspen Zidovudine® 
South African legal status Schedule 4 
Bioavailability 65% 
Half-life 1-2 hours 
Route of administration Oral 
Renal excretion 29% 
Protein binding 30-38% 
 
2.2.1 Mechanism of action 
AZT (a structural analog of thymidine) is a NRTI that undergoes phosphorylation to its 
active metabolite, zidovudine triphosphate (AZT-TP). AZT-TP competes with the 
natural substrate, deoxy guanosine triphosphate (dGTP) for incorporation into viral 
DNA, acting as chain terminator for the synthesis of DNA. It lacks the 3̍-OH group in 
the incorporated nucleoside and it prevents chain elongation by failing to complete the 
5̍ to 3̍ phosphodiester linkage necessary for DNA chain elongation, hence terminating 
viral DNA growth (Figure 2.4).[13] 
http://etd.uwc.ac.za/
 Chapter 2: Literature review 
20 
 
 
Figure 2.4: Structural representation of Zidovudine - mechanism of action  
 
2.2.2 Mechanism of Zidovudine toxicity 
The use of AZT has been associated with adverse effects such as cardiomyopathy, 
neutropenia, hepatotoxicity, anemia and myopathy.[25] Various mechanisms of AZT-
induced toxicity have been postulated to explain how AZT induces toxicity. These 
mechanisms include mitochondrial DNA (mtDNA) depletion, oxidation stress 
(mitochondrial dysfunction), and depletion of l-carnitine.[25] 
mtDNA Depletion 
HIV patients who experience AZT-induced myopathy as an adverse effect have been 
found to present with mtDNA depletion.[46-48] This has led to the deduction that mtDNA 
depletion leads to dysfunction of the electron transport chain, affecting ATP synthesis 
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and oxidative phosphorylation. Aerobic ATP production fails to produce the minimal 
energy needed to maintain organ or tissue functions which leads to dysfunction. This 
however is reversible upon withdrawal of AZT. [46-48] 
Studies show that AZT-induced mtDNA depletion is due to mitochondrial thymidine 
triphosphate pool depletion or inhibition of DNA polymerase, required for DNA 
synthesis and replication. With reference to the metabolism and mechanism of AZT 
action, AZT-TP can indeed inhibit DNA-polymerase; however, there is lack of evidence 
correlating mtDNA depletion and inhibition of DNA polymerase.[49] Literature shows 
that the ability of mtDNA to replicate is hindered by AZT inhibiting thymidine 
kinase,[50,51] leading to mtDNA depletion. Lebrecht et al., (2007) reported that 
administration of dietary supplements rich in uridine to AZT treated mice helped 
attenuate signs of AZT-induced myopathy, mtDNA depletion and markers of oxidative 
stress.[50,52] The mechanism by which uridine functions is not fully understood though 
it is believed to compete with AZT at certain steps such as phosphorylation or 
intracellular transport, or by correcting a pyrimidine deficit.[50,52] 
Oxidative stress 
It has been hypothesized that AZT may impair the electron transport chain. This may 
lead to increased production of reactive oxygen species and oxidative stress, 
eventually causing loss of mtDNA integrity.[53] AZT was reported to cause a decrease 
in ATP concentration. It is also responsible for the depletion of glutathione [53] which 
occurs in conditions of oxidative stress. Glutathione is a cysteine tripeptide whose 
main objective is the elimination of reactive oxygen species.[53] The concentration of 
glutathione was seen to dwindle just six days after administration of AZT; by day 15, 
the values ranged between 32 and 50% of normal levels.[53] Reactive oxygen species 
can cause cellular and mitochondrial dysfunction through damage to DNA, lipids and 
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proteins. There is however no direct evidence to suggest that reactive proteins are 
involved in myopathy and mitochondrial toxicity.[53] The compound, 8-oxo-7,8-dihydro-
2̍-deoxy guanosine (8-oxo-dG), a marker of oxidative damage to DNA and high levels 
of oxidized glutathione, was found in AZT-treated mice compared to the control 
mice;[54] hence showing that  oxidative stress plays a role in AZT-induced myopathy. 
Reduced Mitochondrial Content of L-Carnitine 
L-carnitine is a quaternary ammonium compound involved in the metabolism of long 
chain fatty acids to generate energy. It can be obtained exogenously from the ingestion 
of dairy products and meat and can also be synthesized endogenously from such 
amino acids as methionine and lysine. Evidence suggests that AZT is responsible for 
a reduction in cellular L-carnitine levels which may lead to mitochondrial 
dysfunction,[55-57] promoting accumulation of lipids in the cytoplasm of muscle cells. 
The mechanism by which AZT causes cellular reduction of L-carnitine was shown to 
be by reduction of L-carnitine transport across the plasma membrane.[55] AZT also acts 
as a non-competitive inhibitor of the sodium-dependent transport of L-carnitine. 
If one of these mechanisms of AZT toxicity can be attenuated by non-covalent 
polymeric micelle formulation parameters, it would be another advantage obtained 
from the non-covalent formulation of the AZT complexes. 
2.3 Dosing of TDF and AZT in South Africa 
Tenofovir disoproxil is available in South Africa as tablets of 300 mg administered once 
daily in adults. This dose is modified accordingly in patients with renal impairment. 
Zidovudine is available in South Africa as capsules of 100 mg and tablets of 300 mg, 
generally administered at a dose of 300 mg twice a day. It is also available as an oral 
solution of 10 mg per ml.  
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2.4 Poly-lactic-co-glycolic acid (PLGA) 
Poly (lactic-co-glycolic) acid (PLGA) is a co-polymer of lactic acid and glycolic acid. It 
is considered one of the best biomaterials for drug delivery based on its design, 
performance, excellent biocompatibility, biodegradability, and mechanical strength.[58] 
Among other polymers such as polycaprolactone (PCL), poly-lactic acid (PLA), and 
poly-glycolic acid (PGA), PLGA is one of many polymers registered by the Food and 
Drug Administration (FDA) and the World Health Organization (WHO) as material for 
use in the manufacture or delivery of medicine. PLGA co-polymers are widely used in 
the pharmaceutical industry for controlled delivery of immunomodulatory drugs, 
antiviral agents, anticancer agents, antihypertensive agents, hormones and vitamins. 
Macromolecules such as antibodies, proteins and peptides have also been delivered 
systemically using PLGA. 
In terms of solubility, PLGA is soluble in a wide variety of solvents such as acetone, 
acetyl acetate, and chlorinated solvents. It can be processed into virtually any size or 
shape; and can encapsulate molecules of almost any size. 
2.4.1 Synthesis of PLGA 
PLGA can be synthesized through a polycondensation reaction or ring-opening 
polymerization of cyclic diesters, which is the random co-polymerization of the two 
monomers of cyclic dimers (1,4-dioxane-2, and 5-diones) of glycolic and lactic acid 
(Figure 2.5). The polymers are linked together by ester bonds, and catalysts such as 
tin (II) 2-ethylhexanoate, tin (II) alkoxides or aluminum isopropoxide are used to 
produce amorphous aliphatic polyester products. [59] Ring-opening polymerization can 
be used to synthesize PLGA co-polymer of molecular weight less than 10 kDa (low 
molecular weight polymer). 
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Figure 2.5: Schematic representation; synthesis of PLGA (n represents the 
number of lactic acid units while m represents the number of 
glycolic acid units). 
  
2.4.2 Chemistry 
The physiochemical properties of PLGA provide it with the ability to entrap hydrophilic 
drugs and deliver them at the required site. Formulations with PLGA may therefore 
control drug release rate and increase drug absorption; a feature which may be 
employed to minimize drug-related adverse effects.[60] The two monomers, poly lactic 
acid (PLA) and poly glycolic acid (PGA) differ in composition: PLA has an asymmetric 
α-carbon which is described as the D or L form while PGA lacks any asymmetric α-
carbon. The different forms of PLA are poly D-lactic acid (PDLA) and poly L-lactic acid 
(PLLA). PLA has a methyl group in its structure which makes it hydrophobic in nature. 
This polymer can be manufactured from the two isomers, PDLA and PLLA. The 
inactive racemic mixture, D-lactic acid, is transparent and amorphous in nature due to 
the irregular distribution of the D and L units whereas the optically active L-lactic acid 
is semi-crystalline in nature.[61,62] The disordered nature of PLA’s polymer chains also 
permits it to form crystalline (PLLA) or amorphous (PDLA) structures, while its 
similitude, PGA, lacks any methyl side groups, hence its ability to form highly 
crystalline structures.[58] This crystallinity is however lost in PLGA copolymers. 
Amorphous PLGA copolymers are best suited for applications in drug delivery as 
discussed by Gilding and Reed (1979), reason being that amorphous PLGA provides 
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a homogenous dispersion of the active pharmaceutical ingredient (API) in the polymer 
matrix. In the preparation of PLGA using L-lactic acid with glycolic acid of 25-70%, the 
copolymer produced is amorphous. For an amorphous D-lactic acid, the ratio of 
glycolic acid extends from 0-70%; hence the preference for using D-lactic acid in the 
composition of PLGA as compared to the L-isomer lactic acid.[61]  
As earlier mentioned, PLA is more hydrophobic and is always in a greater percentage 
in PLGA formulations than glycolic acid. Therefore, a lactide-rich PLGA composition 
implies that the co-polymer will be hydrophobic. A hydrophobic polymer will absorb 
less water and will subsequently degrade slowly due to hydrolysis. Studies have 
shown that PLGA formulations with a ratio of PLA (50):PGA (50) are an exception to 
this rule, being found to have the fastest degradation rate and shortest half-life.[58,60] 
This ratio is the most frequently used in preparations. Other ratios of PLGA such as 
85:15 and 75:25 have also been used to deliver various drugs such as paclitaxel and 
rifampicin, while the 50:50 ratio has been used for folic acid delivery. The proportion 
or molar ratio of each polymer in a PLGA co-polymer therefore influences the rate at 
which the encapsulated drug is released.[58,63,64] 
2.4.3 The effect of particle size and size distribution 
The spherical shape and narrow distribution of the polymer play a very important role 
in the controlled release of an encapsulated drug from the polymer matrix in the 
body.[65] Interaction and adhesion of the nanoparticles with the cells are largely 
influenced by the shape and sizes of the nanoparticles. Morphology and porosity also 
influence the concentration and rate of drug release from the polymer.[66] The 
morphology of the particles is influenced by properties such as composition, molecular 
weight, synthesis conditions and chemical structure of the polymer.[65,67] The direct 
correlation between these parameters and particle morphology have however not 
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been sufficiently studied, leading to many research areas. Some postulated 
mechanisms of how particles pass through the gastrointestinal and physiological 
barriers include:  
1. Endocytosis: The uptake of particles is mainly through absorption by the 
intestinal enterocytes via endocytosis. This process mainly absorbs particles < 
500 nm.  
2. Paracellular passage: The extremely small size of the nanoparticles enables 
them to knead between intestinal epithelial cells, mainly particles with a size < 
50 nm.  
3. Lymphatic passage: Particles < 5 μm are mainly absorbed by microfold cells in 
Peyer’s patches of the intestinal tract. Peyer’s patches are small masses of 
lymphatic tissue normally found in the small intestine, which function to prevent 
growth of pathogenic bacteria and also monitors bacteria population in the 
intestine.[68] Lymphatic passage in Peyer’s patches has been demonstrated by 
Jani et al where particles with mean diameters between 50 and 100 nm were 
proven to have a higher uptake rate in a rat’s intestine compared to larger 
particles.[69] It was observed that after the administration of equal doses, 26% 
of the 100 nm and 34% of the 50 nm were detected in gut-associated lymphoid 
tissues and the intestinal mucosa. With nanoparticle sizes less than 500 nm, 
only 10% of the particles were detected in intestinal tissues, and particle sizes 
greater than 1 μm exhibited low uptake and were exclusively found in Peyer’s 
patches. Particle sizes greater than 3 μm were occasionally found in the follicle-
associated epithelia.[69,70] The smallest capillaries in the body range between 5 
and 6 μm in diameter; therefore, particle distribution in the bloodstream should 
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be targeted below 5 μm. Care should also be taken to ensure that such particles 
do not aggregate.  
Several advantages are inherent in the production of nanoparticles with small 
sizes. One advantage of making such small nanoparticles (less than 220 nm) is 
that they can be easily sterilized by filtration because bacteria and viruses are 
larger.[67] Figure 2.6 presents the different nanoparticle size ranges with examples 
of various materials that can easily attain such sizes, along with  examples of bio-
nanoparticles. 
 
Figure 2.6: Schematic representation of bio-nanoparticles and nanoparticle sizes 
(nanometer scale) (Wich Research Lab, 2018) 
2.4.4 Degradation 
The degradation of PLGA is not confined to its surface. In an aqueous environment, 
PLGA undergoes heterogeneous or bulk erosion. Four distinctive steps – viz 
hydration, initial degradation and progressive degradation, and solubilization, can be 
experienced during PLGA degradation. [64]  
2.4.4.1 Hydration 
The amorphous region of the polymer is penetrated by water. This disrupts forces such 
as hydrogen bonds and weak van der Waals forces, resulting in a decrease in the 
polymer’s glass transition temperature (Tg).[64] 
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2.4.4.2 Initial degradation 
The molecular weight of the polymer decreases, and cleavage of the covalent bonds 
occurs. 
2.4.4.3 Progressive degradation 
The degradation process is auto-catalyzed by the carboxyl end groups. This is 
because of the hydrolytic reactions taking place, hence cleavage of the backbone 
covalent bonds leading to loss of mass and integrity. 
2.4.4.4 Solubilization 
The cleaved fragments of the polymer are further cleaved to smaller molecules that 
are soluble in an aqueous environment. The end products after degradation are lactic 
acid and glycolic acid (Figure 2.7). These monomers are metabolized and eliminated 
via the Krebs cycle as water and carbon dioxide, [71,72] hence produce minimal, if any, 
systemic toxicity in the body. Figure 2.7 hydrolysis of PLGA shows how the copolymer 
is broken down into glycolic acid and lactic acid. 
 
Figure 2.7: Hydrolysis of PLGA  
The proportion of each monomer in the co-polymer (PLGA) affects its overall 
physicochemical properties and its ability to undergo degradation. Factors such as 
mechanical strength, molecular weight, swelling behavior, characteristics of the 
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surrounding medium, stereochemistry, end-group functional groups chemical 
derivation and co-polymer composition, also affect the polymer’s capacity to undergo 
hydrolysis to its original monomers, lactic acid and glycolic acid. [60] 
2.4.5 Polymer composition 
The ratio of lactic acid to glycolic acid in PLGA is very important for control of the 
degradation process. Lactic acid is more hydrophobic than glycolic acid; this entails 
that a lactide-rich PLGA will absorb water more slowly and degrade more slowly 
compared to a glycolic-rich PLGA. 
2.4.5.1 Stereochemistry 
The degradation process of PLGA is greatly affected to a certain degree by the D- and 
L- forms of PLA. This is because water penetration of the L- form is slower compared 
to the D- form, hence a faster degradation of the D-form.[73] 
2.4.5.2 Functional group 
The terminal functional group affects the physicochemical properties of PLGA to an 
extent. In vivo studies have shown that an ester-terminated PLGA’s degradation time 
can be delayed for about four to six weeks compared to an acid-terminated PLGA of 
the same composition and molecular weight. [73] 
2.4.5.3 Chain length 
Chain length is a very important consideration in the choice of a polymer. The 
polymer’s degradation speed and its physical strength are influenced by the molecular 
weight of the polymer. It has been shown that increasing the molecular weight of the 
polymer from 10 to 100 kDa increases the degradation rate of the polymer from weeks 
to months. [74,75] 
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2.4.5.4 Chemical derivation 
The hydrophobicity of PLGA can be decreased by attaching a hydrophilic moiety 
(hydroxyl group). A mixture of PLGA and the hydroxyl moiety exhibits a stronger 
affinity for water than PLGA without a hydroxyl moiety.[76,77] 
2.4.5.5 Characterization of the surrounding medium 
The medium surrounding the polymer also influences the degradation process. As an 
example, autocatalysis can be initiated or experienced in an acidic environment; thus, 
the degradation process is accelerated in acidic conditions compared to non-acidic 
environments.[78] 
2.4.6 Mechanism of drug release 
A series of rate limiting steps are involved in the release of a drug from a polymer until 
exhaustion. There are a few different mechanisms by which an encapsulated drug can 
be released from the polymer (Figure 2.8). These mechanisms include erosion, 
degradation of the polymer matrix, diffusion, solvent penetration and polymer swelling. 
A combination of all these mechanisms may sometimes be involved in the release of 
drug from the polymer; with different mechanisms occurring at different time 
intervals.[79] 
Figure 2.8: Possible mechanisms of drug release from PLGA (Lanao et al., 2013)[79]  
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With advances made in nanotechnology, several studies have been employed using 
non-polymeric or polymeric nano-carriers (e.g., micelles or encapsulation into nano 
conjugates)[80-83] as a means of resolving some of the earlier-mentioned 
disadvantages associated with the use of these APIs (TDF and AZT). Nanoparticles 
are advantageous as delivery vehicles; they provide a large surface area to volume 
ratio and are biomimetic.[84-86] They have been used to enhance oral bioavailability of 
several drug classes that have low solubility, chemical instability and poor permeation.  
Looking at literature, several attempts have been employed by various authors 
demonstrating the preparations of AZT and TDF into nanoparticles, these authors had 
one goal which was to optimize the delivery and use of these APIs using PLGA while 
employing various methods for such formulations. Some of such studies include but 
are not limited to the following (Table 2.5) 
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Table 2.5: Studies performed by various authors on TDF and AZT involving the use 
of PLGA nanoparticles 
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The distinct difference in the studies performed by the above-mentioned authors was 
their formulation method and the polymer ratio used for the preparation of the nano-
formulations (Table 2.5). Each author used a unique approach to increase the 
encapsulation efficiency to get better nanoparticle uptake such as coating the 
nanoparticles (Peter Christoper et al., 2014) or even using conjugates (Dalpiaz et al., 
2013) etc. 
This study shares similarities such as the objective of improving the encapsulation of 
the APIs, use of PLGA 50:50 ratio used by several of the authors in Table 2.5 and 
optimizing the delivery of AZT and TDF for the management of HIV using PLGA. 
However, this study focused on developing a method (modified version of the double 
emulsion water-in-oil-in-water solvent evaporation/diffusion method) different from 
those mentioned above which aimed to produce small nanoparticles to facilitate an 
increase in absorption in the intestines and lymphatic system, thereby increasing 
bioavailability with increased encapsulation efficiency. The study also makes use of 
another PLGA ratio (85:15) to compare similarities and differences of AZT and TDF 
nano-complexes using both ratios. 
Chapter 3 presents the methodology for the research. It provides details of the various 
steps taken to prepare the nano-formulation, characterize the formulations and 
comparatively test the release profiles. 
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CHAPTER 3: METHODOLOGY 
This chapter gives a detailed account of the materials, methods and analytical 
techniques used in this study. A clear description of the analytical techniques and 
procedures used is provided in a chronological order.  
3.1 MATERIALS  
3.1.1 The active pharmaceutical ingredients (APIs)  
Tenofovir disoproxil fumarate (TDF) and Zidovudine (AZT) powders, batch numbers 
BTDFVSP14261113 and ZD3911013, respectively, were donated by Aspen 
Pharmacare, South Africa. 
3.1.2 Chemicals and reagents  
Polymer: Resomer® RG 504 ester terminated, lactide: glycolide 50:50, Mw 38,000-
54,000 g/mol (Sigma-Aldrich, Germany), Poly D,L-lactide-co-glycolide 85:15 ester 
terminated, Mw 50,000-75,000 g/mol (Sigma-Aldrich, Germany), HPLC grade 
methanol, HPLC grade orthophosphoric acid, sodium dihydrogen orthophosphate 
dehydrate (Sigma-Aldrich, South Africa), D-α-tocopherol polyethylene glycol succinate 
(TPGS) (Sigma-Aldrich, Germany), gelatin, tween 80, ethyl acetate, acetone (Sigma-
Aldrich, South Africa), phosphate buffer solution contents (sodium chloride, potassium 
chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate), sodium 
hydroxide, and hydrochloric acid (Sigma-Aldrich, South Africa). 
3.2 INSTRUMENTS   
Homogenizer (IKA® T18 digital Ultra-Turrax®, Germany), sonicator (Sonoplus HD GM 
2070, Bandelin, Germany), centrifuge (Beckman Coulter Allegra® 64R, UK), analytical 
balance (Mettler®, model P.E 6000, USA), infrared spectrophotometer (Perkin-Elmer 
100 FTIR instrument fitted with UATR, controlled with Spectrum® software version 
6.3.5, USA), differential scanning calorimeter (Perkin-Elmer PC7 series, USA), 
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thermogravimetric analyser (Perkin-Elmer PC thermal system, USA), scanning 
electron microscope (Auriga HR-SEM F50, Zeiss, South Africa), hot stage microscope 
(a Linkam T95 temperature control unit connected to Linkam TH MS600), ultra violet 
spectrophotometer (Cintra 202, GBC Scientific Equipment, Australia), deep freezer 
(Sanyo, USA), particle size analyzer (Zeta sizer Nano ZS Malvern Instruments Ltd, 
UK), lyophilizer (Virtis freeze dryer freeze mobile model 125L; Malvern Instruments, 
Ltd, UK), pH meter (Basic 20, Lasec, South Africa), vortexer (Benchmark Scientific 
Inc, BV1000 vortex mixer, Taiwan), micropipettes (Eppendorf, Hamburg, Germany), 
water purification system (Milford, MA, USA), bath sonicator (Ultra-sonic Model 702, 
100W, Voltage 2030V, LABOTEC, South Africa), rotary evaporator (Buchi, LABOTEC, 
South Africa), orbital shaker- Incubator ES-80 (Grant bio, monitoring and control 
laboratories, South Africa),  HPLC Column (Luna® C18 analytical column 250 x 4.6 mm, 
i.d 5µm), HPLC-system (Agilent 1200 series) fitted to a quaternary pump (G1311A, 
Germany), degassing system (G1322A, Japan), auto loading sampler (G1329A, 
Germany),Thermostat column compartment (G13164, Germany), diode array detector 
(G1315B, Germany), fluorescence detector (G1521A Germany), Agilent ChemStation 
software (G2173-60101L, Germany), analyte fraction collector (G164C, Germany) 
3.3 IDENTIFICATION TECHNIQUES  
Identification tests were performed on TDF, AZT, both ratios (50:50 and 85:15) of poly-
lactic-co-glycolic acid (PLGA), physical mixtures of TDF with PLGA and physical 
mixtures of AZT with PLGA. Each API and each different polymer ratio were mixed in 
a ratio of 1:10 and triturated in a mortar with pestle to obtain uniform mixing. The 
resulting physical mixture was transferred into a vial for storage. Samples were 
withdrawn from the vial and analyzed using the following analytical techniques: 
Differential Scanning Calorimetry (DSC), Thermogravimetric Analysis (TGA), Fourier 
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Transform Infrared Spectroscopy (FT-IR) Hot Stage Microscopy (HSM) and Scanning 
electron microscopy (SEM). 
3.3.1 Differential Scanning Calorimetry (DSC) 
A Perkin Elmer DSC 7 series connected to a Perkin Elmer thermal analysis controller 
TAC7/DX and a Perkin Elmer gas station were used for this stage of the study. About 
1.5 - 3 mg of sample was weighed into an aluminum pan which was then crumpled. 
An empty aluminum pan of the same dimensions was crumpled and used as a 
reference. The samples were analyzed at an increasing temperature rate of 10°C/min, 
with nitrogen as the carrier gas at a flow rate of 20 ml/min. Samples were heated over 
the temperature range, 30 - 460°C, and Pyris™ software was used to collect and 
analyze the data.  
3.3.2 Thermogravimetric analysis (TGA) 
The analysis was performed using a Perkin Elmer thermogravimetric analyzer TGA 
4000, with the flow rate of nitrogen gas at 20 ml/min. An empty porcelain pan was 
tarred, the sample placed in the porcelain pan and the weight of the sample recorded. 
Samples were analyzed over a temperature range from 20 - 600°C at an increasing 
temperature rate of 10°C per minute. Data was collected and analyzed using Pyris™ 
software.  
3.3.3 Fourier Transform Infrared Spectroscopy (FT-IR)  
FT-IR analyses of the nano-formulations were carried out for AZT and TDF nano-
formulations made with PLGA (50:50 and 85:15) polymers, using a Perkin Elmer 100 
FTIR spectroscope to confirm inclusion of the API’s in the nano-formulation. All the 
spectra were collected using Spectrum® software version 6.3.5. The FT-IR spectra of 
the complexed formulations were compared to that of the APIs alone. Differences or 
changes in the characteristic bands of the complexed formulations such as 
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appearance, disappearance, variations in peak intensity, and shifts in wave number 
or broadening can be indicative of complex formation. The parameters mentioned 
above aid in understanding of the physical characteristics of drug/polymer interactions. 
The infrared absorption spectra were collected at 20°C from 4000 to 650 cm–1. 
3.3.4 Hot stage microscopy (HSM) 
This is an analytical technique often used in collaboration with DSC to substantiate 
and elucidate the results obtained from DSC, hence confirming the thermal curves 
obtained in DSC analysis. A small amount of the nano-formulation was placed on a 
thin plate of glass and a small drop of silicon oil was used to lubricate the sample. 
Silicon is an inert element widely used in such procedures because of its lubricating 
properties and its relatively high thermal stability. Samples were heated at a 
temperature increase rate of 10°C per minute over a temperature range from 20°C to 
200°C. This temperature range included the anticipated melting points of the APIs and 
polymers. The samples were observed under a microscope and images taken at 
specific temperature intervals for analyses. The heater was connected to an Olympus 
US30 color video camera and the temperature control was a Linkam TH MS600 
connected to a T95 linkpad system controller. Images were recorded using the stream 
Essential® software. 
3.3.5 Scanning Electron Microscopy (SEM) 
Scanning electron microscopy is a high-resolution imaging analytical technique used 
to take images of nanoparticles. It is generally used to the study particle morphology 
of the sample. The sample is bombarded by a beam of electrons from thermal 
emission. The interaction between the atoms from the sample and the electrons 
released presents various signals that in turn provide information on the particle’s 
morphology and composition.  
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The freeze-dried nano-complexes were smeared on a double-sided carbon adhesive 
tape attached to an aluminum stub and dried in a fume hood. Thereafter, the nano-
complex formulation was coated with gold palladium using an Emitech™ K550X 
(England) sputter coater. Images were captured using an Auriga™ F50 high resolution 
scanning electron microscope (HR-SEM), at 6.6 mm and a voltage of 5 kV as the 
operating parameters. 
3.4 Formulation process  
3.4.1 Preparation of nanoparticles 
The preparation of nanoparticles was achieved using a modified version of the double 
emulsion (water-in-oil-in-water) solvent evaporation and diffusion method.[1] The steps 
taken to modify and brief discussion to this eventual method can be seen in Appendix 
A and B. 
Final preparation method of AZT-PLGA and TDF-PLGA nanoparticles 
A specified amount (100 mg) of the polymer was weighed on an electrical balance. 
The weighed polymer was placed in a 50 ml test tube and dissolved in 10 ml mixture 
of ethyl acetate (EA)/acetone (ACE) at a ratio of 4:1, at which the ensuing mixture had 
small particle sizes (appendix A). The solution was vortexed to form a polymer 
solution. An aqueous phase was prepared by dissolving 5 mg of the active 
pharmaceutical ingredient (API) in 1 ml of distilled water containing 0.2% w/v tween 
80. This mixture was vortexed to ensure that the drug was properly dissolved. The 
aqueous phase was dropped gradually into the polymer solution and homogenized for 
2 minutes at a speed of 5000 revolutions per minute (rpm) in an ice bath. The mixture 
was then probe-sonicated at 87 W energy output (amplitude 87%) for 30 seconds to 
produce the primary water-in-oil emulsion (w/o). The primary emulsion was poured 
gradually into 40 ml of water containing 0.12% D-α-tocopherol polyethylene glycol 
succinate (TPGS). This was homogenized for 3 minutes at a speed of 12000 rpm, then 
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probe sonicated at 87 W energy output (amplitude 87%) for 2 minutes under an ice 
bath to produce the double water-in-oil-water emulsion (w/o/w). The w/o/w emulsion 
was solidified by pouring the emulsion into 40 ml of water containing 0.2% tween 80 
while stirring at a speed of 800 rpm. The organic phase was evaporated using the 
rotary evaporator at a speed of 400 rpm and temperature of 34 ± 1°C for 8 hours. 
3.4.1.1 Separation of nanoparticles  
After evaporation of the organic solvents (EA and ACE), the nanoparticles were 
collected by pouring the emulsion into 40 ml oak ridge centrifuge tubes. The tubes 
were then centrifuged at a speed of 16500 rpm at 1°C for 1 hour. The supernatant was 
discarded while ensuring minimum disruption of the nanoparticles (pellets). The 
contents of the centrifuge tubes were collected into one test tube and washed three 
times with distilled water.  
3.4.1.2 Lyophilization of nanoparticles 
The method of choice to remove water from the nanoparticles was lyophilization, also 
known as freeze drying. Freeze drying aided in overcoming drug leakage and stability 
issues such as aggregation. The nanoparticles, after collection and washing, were 
frozen at a temperature of -70°C and lyophilized to remove the water content. They 
were then stored between 2 and 8°C and subsequently characterized. 
The percentage recovery of the formulated particles was calculated from Equation 3.1 
below:  
 𝑁𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (%) =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑃𝐿𝐺𝐴 𝑎𝑛𝑑 𝑑𝑟𝑢𝑔 𝑢𝑠𝑒𝑑 
𝑥100  
Equation 3.1 
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3.4.2 Nanoparticle characterization 
The following analyses were performed to characterize the nanoparticles: particle size 
analysis, polydispersity index, zeta potential, percentage yield, drug entrapment 
efficiency, encapsulation efficiency, FT-IR spectra, DSC, TGA, SEM, and HSM.  
3.4.2.1 Particle size analysis  
Dynamic light scattering was used to determine the nanoparticle sizes. The instrument 
used was a Nano-Zeta sizer from Malvern®. This measures the intensity of scattered 
light which occurs because of the particles being in constant Brownian motion, thus 
providing information about the particulate system. The particle sizes of nano-
formulations are very important because they determine parameters like 
physicochemical properties, biological half-life and distribution in the body.[2] The 
measure for width of size distribution is called polydispersity index (PDI). Values of 
PDI closer to one (1) indicate a heterogeneous distribution of nanoparticles while 
values closer to zero (0) indicate a homogenous distribution of nanoparticles. Particles 
sizes were measured immediately after formulation. After collection and after freeze-
drying, a small sample of the freeze-dried nano-complex was dispersed in water as a 
medium, placed in cuvettes (zeta cells) and analyzed. The measurements were all 
taken in triplicate and the average reported. 
3.4.2.2 Zeta potential  
Following collection of the pellets and freeze drying, the Malvern® Zetasizer was used 
to determine the charge of the particles immediately after solvent evaporation. A small 
sample of the freeze-dried nano-complex was dispersed in distilled water, vortexed 
and analyzed. The measurements were done in triplicate and the average and 
standard deviation (SD) values reported. 
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3.4.2.3 Percentage yield  
This is the total amount of nanoparticles recovered after formulation expressed as a 
percentage. The formulated powder was weighed immediately after retrieval from the 
freeze drier. The percentage yield of TDF-PLGA and AZT-PLGA complexes was 
determined using the following formula: 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑦𝑖𝑒𝑙𝑑(%) =
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑃𝐿𝐺𝐴, 𝑑𝑟𝑢𝑔 𝑎𝑛𝑑 𝑒𝑥𝑐𝑖𝑝𝑖𝑒𝑛𝑡𝑠
 𝑢𝑠𝑒𝑑 𝑖𝑛 𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 
𝑥100 
Equation 3.2 
3.4.2.4 Drug entrapment efficiency  
Drug entrapment efficiency is defined as the ratio of the drug loaded in the polymer to 
the theoretical amount of drug expected to have been loaded. To determine this, the 
theoretical and actual drug loading percentages were first determined, using the 
following equations:  
 𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (𝑇𝐷𝐿)(%)
=
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑 
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 𝑎𝑛𝑑 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑 
𝑥 100  
Equation 3.3 
𝐴𝑐𝑡𝑢𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (%) =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
𝑥100 
Equation 3.4 
 
𝐷𝑟𝑢𝑔 𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦(%) =
𝑎𝑐𝑡𝑢𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 
𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 
𝑥100 
Equation 3.5 
3.4.2.5 Encapsulation efficiency  
The encapsulation efficiency determines the actual amount of drug found in the nano-
complex after formulation. The amount of drug encapsulated in the polymer was 
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determined by dissolving 5 mg of the nano-complex in 0.5 ml of ethyl acetate (in a 5 
ml Eppendorf tube) with vortexing. The ethyl acetate was evaporated, and 3 ml of 
phosphate buffer solution (PBS) was added to the Eppendorf tube. The tube was 
vortexed, and the contents centrifuged at a speed of 10000 rpm for 15 minutes. 
Thereafter, the supernatant was collected, and the absorbance measured using the 
UV-spectrometer and HPLC-DAD system. The concentration of the drug in that 
sample was determined by extrapolating the absorbance value from a calibration plot 
of the APIs. The amount of API and the encapsulation efficiency was determined using 
the equation below: 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦(%)   
=   
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑡ℎ𝑒 𝑦𝑖𝑒𝑙𝑑 
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑 𝑑𝑢𝑟𝑖𝑛𝑔 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 
𝑥100 
Equation 3.6  
3.4.2.6 In-vitro drug release  
In-vitro release kinetics of TDF and AZT loaded nanoparticles was carried out as 
described by Cetin, Atila and Kadioglu (2010) with slight modifications (sample and 
separate method).[3,4] Weighed amounts (20 mg) of each nano-formulation was 
suspended in an Eppendorf tube with 1 ml of PBS (at either pH 1.2 or pH 7.4) 
containing 0.1% v/v of tween 80. The sample was incubated at 37°C in a shaker 
incubator at 120 rpm. Subsequently, 0.5 ml was withdrawn with replacement at 
predetermined time intervals. The isolated samples were centrifuged at 15000 rpm for 
20 minutes and the supernatant analyzed for drug content by the UV-spectrometry 
and HPLC-DAD methods described below. 
3.5 Preparation of phosphate buffer solution (PBS) - pH 7.4 and pH 1.2 for in-
vitro release  
3.5.1 Ingredients  
Sodium chloride = 8 g  
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Potassium chloride = 0.2 g  
Disodium hydrogen phosphate = 1.44 g  
Potassium dihydrogen phosphate = 0.24 g  
The above ingredients were weighed and ground in a mortar with pestle. Thereafter, 
the ingredients were dissolved in 800 ml of distilled water, while being stirred with a 
stirring rod to ensure that the solutes dissolved completely. The pH of the solution was 
measured and adjusted to 1.2 and 7.4 using 0.1 M hydrochloric acid. The final volume 
was adjusted to 1000 ml with distilled water. The solution was autoclaved to denature 
any microbiological contamination, allowed to cool and stored for use.  
3.6 Method development 
Two analytical techniques, that is, ultra violet-visible (UV-VIS) spectrometry and 
high-performance liquid chromatography with diode array detection (HPLC-DAD), 
were used to characterize and quantify the amount of drug encapsulated and 
released from the formulated nanoparticles. 
3.6.1 Validation of UV-VIS spectrophotometer analytical procedure for 
quantification of tenofovir disoproxil fumarate and zidovudine in 
nanoparticles. 
Preparation of standards for calibration  
A stock solution was prepared by dissolving 5 mg of API in 100 ml of PBS (at pH 1.2 
or pH 7.4) with sonication (for 1 minute) to ensure complete dissolution of the API. 
Serial dilutions of the stock solution were performed to obtain working solutions of 2 
µg/ μl, 4 µg/ μl, 6 µg/ μl, 8 µg/ μl, 10 µg/ μl and 12 µg /μl.  
Determination of range and linearity  
The absorbance of each API at a specific concentration was measured using the UV-
VIS spectrophotometer. A measured amount (3 ml) of PBS solution (at pH 1.2 or pH 
7.4) was placed into two quartz cuvettes. The cuvettes were scanned at the lambda 
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maxima (λmax) of 260 nm and 266 nm for TDF and AZT, respectively, and the blank 
readings were recorded. Thereafter the absorbance of the APIs at different 
concentrations was measured. Readings were done in triplicate and the mean values 
were used to plot a graph of absorbance versus concentration (µg/ ml).  
Determination of accuracy and precision  
The accuracy and precision for the method employed in this study was determined 
thus: three concentrations of the API within the calibration range were used. The 
precision was determined by inter-day (intermediate precision) and intraday 
(reproducibility) analyses. Over a period of three consecutive days, the samples were 
assayed and the average readings, standard deviation and % relative standard 
deviation (RSD) were calculated and compared to determine the inter-day and intra-
day precision. The accuracy of the method was determined by taking the mean of the 
measurements and calculating the percentage difference. All readings and 
measurements were done in triplicate. 
3.6.2 Validation of HPLC-DAD analytical procedure for quantification of 
tenofovir disoproxil fumarate and zidovudine in PLGA-nanoparticles  
Chromatographic conditions  
The mobile phase comprised of HPLC grade methanol and phosphate buffer (sodium 
dihydrogen orthophosphate, 10 mM, at pH 5.0) mixed in a ratio of 70:30 (v/v), and 
operated at a flow rate of 0.8 ml/min. A Luna C18 column (250 mm x 4.6 mm, 5 μm) 
was used as the stationary phase. Samples were analyzed over a range of 
wavelengths from 254 to 266, with the specific wavelengths of interest at 260 nm and 
266 nm for TDF and AZT, respectively.  
Preparation of standards for calibration  
Stock solutions were prepared by dissolving 4 mg of the API (TDF and AZT) in 200 ml 
of PBS (at pH 1.2 or pH 7.4) with sonication (for 1 minute) to ensure complete 
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dissolution of the API. Serial dilutions of the stock solution were performed to obtain 
working solutions of 0.02 µg/ μl, 0.04 µg/ μl, 0.06 µg/ μl, 0.08 µg/ μl, 0.10 µg/ μl and 
0.12 µg/ μl. 
Optimization of chromatographic conditions  
The HPLC method was based on the method developed by Bhavsar et al (2012) with 
some slight modification to the flow rate. The final chromatographic conditions 
consisted of 70 volumes of methanol to 30 volumes of PBS (pH adjusted to 5.0 using 
10% orthophosphoric acid) as the mobile phase. A flow rate of 0.8 ml/min was 
observed to be suitable for elution for both APIs within 10 minutes, with good 
symmetrical peaks that were acceptable when compared to those obtained at a flow 
rate of 1.0 ml/min. The final column temperature was set to 40°C. 
Method validation  
The method for simultaneous estimation of TDF and AZT separately in PLGA 
nanoparticles was developed and validated in accordance with the International 
Conference on Harmonisation (ICH) guidelines [5,6]. 
Linearity  
The linearity of the method was assessed by preparing standard solutions of different 
concentrations (0.02 µg/ μl to 0.12 µg/ μl) for both TDF and AZT in different PBS 
solutions (at pH 1.2 or pH 7.4). Each preparation and measurement was done in 
triplicate as per the chromatographic conditions mentioned above. The obtained peaks 
were used to plot a graph of absorbance against concentration to obtain a calibration 
graph for each compound (API). 
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Sensitivity 
The sensitivity of the analytical method was evaluated by determining the limits of 
detection (LOD) and the limits of quantification (LOQ) in accordance with the ICH 
guidelines.  
Determination of accuracy and precision  
The accuracy and precision for this method was determined by taking sample readings 
in triplicate. Three concentrations of the API within the calibration range were used, 
and the precision was determined by inter-day (intermediate precision) and intraday 
(reproducibility) analyses. Over a period of three consecutive days, the samples were 
assayed and the average values, standard deviation and % relative standard deviation 
(RSD) were compared to determine the inter-day and intra-day precision. The 
accuracy of the method was determined by the percentage difference of the mean 
measurements. 
3.7 Assessment of loaded nanoparticle stability  
Following preparation, the nano-formulations were stored between 2 and 8˚C. The 
particle size, zeta potential and PDI were assessed over a period of 10, 20, 30, 60 and 
90 days after formulation. 
 
Chapter 4 will follow with the results obtained during formulation and characterization 
of the formulated nanoparticles using TDF, PLGA 50:50 and PLGA 85:15. 
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CHAPTER 4: RESULTS AND DISCUSSION FOR TENOFOVIR DISOPROXIL 
FUMARATE LOADED NANOPARTICLES  
This chapter presents the results and discussion obtained when Tenofovir disoproxil 
fumarate (TDF) was investigated. Emphasis is placed on the different ratios of poly-
lactic-co-glycolic acid (PLGA 50:50 and 85:15) used in this study.  
4.1 Introduction  
The objective of this study was two-fold of which the formulation of TDF as a 
nanoparticle presented the following specific sub-objectives:  
❖ to characterize TDF and PLGA (50:50 and 85:15) 
❖ to formulate non-covalent complexes of TDF with PLGA of different ratios 
(50:50 and 85:15); 
❖ to characterize and compare physicochemical properties of the formulated 
complexes using various analytical techniques;  
❖ to compare the pharmaceutical properties (i.e. particle size, stability and in-vitro 
release) of both formulations (TDF-PLGA 50:50 and TDS-PLGA 85:15) as a 
means of addressing some of the limitations associated with optimal oral 
delivery of TDF (i.e. low permeability, low bioavailability).  
4.2 Characterization of TDF and PLGA (50:50 and 85:15) 
Prior to formulation of the nanoparticle proper, TDF and two PLGA ratios (PLGA 50:50 
and PLGA 85:15) were characterized individually, and in combination as a physical 
mixture (TDF-PLGA 50:50 and TDF-PLGA 85:15). Data from the characterization 
studies are as follows:  
4.2.1 Fourier-transform infra-red (FT-IR) spectroscopy  
Infra-red spectroscopy (FTIR) was used to identify the functional groups in TDF, PLGA 
(50:50 and 85:15), and the TDF-PLGA (50:50 and 85:15) formulations. This was done 
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to identify the susceptibility of these functional groups to chemical reactions via 
reduction in band intensities or complete disappearance of characteristic bands. The 
samples were also used as reference samples for assessment of the nano-formulation 
process. Figure 4.2 presents the spectra of TDF, PLGA 50:50, PLGA 85:15 and a 
combination of TDF-PLGA 50:50 and TDF-PLGA 85:15 physical mixtures. TDF was 
ground with each polymer separately to form the physical mixtures. The FTIR spectra 
of these mixtures were compared to those of the single component compounds (TDF, 
PLGA 50:50 and PLGA 85:15) to identify characteristic functional groups as a physical 
mixture, as well as the appearance of or disappearance of such functional groups in 
the combination (Figure 4.2 and Table C1.3 in appendix C). 
TDF (Figure 4.2a) showed a characteristic peak band at 3459.12 cm−1, attributed to 
the N-H stretching vibration bands of the amine group. The intensity bands at 2981.38 
cm−1 and 2814.22 cm−1 were assigned to the hydroxyl (O-H) stretching, the band at 
2081.44 cm−1 was attributed to the C=C, and the intensity bands at 1752.31 cm−1 and 
1671.87 cm−1 were assigned to C=O. Figure 4.1a presents the structure of TDF. 
The pure PLGA 50:50 (Figure 4.2b) showed characteristic peak bands at 2950.52 
cm−1 which was attributed to the chelated O-H stretching vibrations. The peak band at 
1750.32 cm−1 was attributed to the C=O stretching of the carbonyl group. The pure 
PLGA 85:15 (Figure 4.2c) also showed characteristic peak bands at 2996.25 cm−1 
which was attributed to chelated O-H bridge stretching and 1746.64 cm−1 attributed to 
strong C=O stretching of the carbonyl group. Figure 4.1b below presents the structure 
of PLGA. 
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Figure 4.1: Structure of (a) TDF  and (b )PLGA (n represents the number of lactic acid 
units while m represents the number of glycolic acid units) 
 
 
Figure 4.2: FT-IR spectra of (a) TDF, (b) PLGA 50:50, (c) PLGA 85:15, (d) TDF-PLGA 
50:50 physical mixture, (e) TDF-PLGA 85:15 physical mixture 
http://etd.uwc.ac.za/
Chapter 4: Results and discussion of TDF PLGA nanoparticle 
65 
 
The FT-IR spectra of TDF-PLGA 50:50 and TDF-PLGA 85:15 physical mixtures 
(Figure 4.2d and Figure 4.2e, respectively) showed shifts in the characteristic peak 
bands of the components in the resulting physical mixture. TDF-PLGA 50:50 physical 
mixture (Figure 4.2d) showed characteristic peak bands at 2993.81 cm−1, attributed to 
chelated O-H bridge stretching and at 1750.07 cm−1, attributed to the C=O stretching 
vibration. The peaks at 3459.12 cm−1 2814.22 cm−1 2081.44 cm−1 and 1671.87 cm−1 
had disappeared while the intensity of the peak at 1752.31 cm−1 had increased when 
compared to the parent AZT. On the other hand, TDF-PLGA 85:15 physical mixture 
(Figure 4.2e) also showed similar characteristic peak bands at 2985.88 cm−1 attributed 
to chelated O-H bridge stretching, and at 1754.32 cm−1 and 1674.85 cm−1, both 
attributed to the C=O stretching vibration. The spectra also presented with peaks that 
had disappeared just like in AZT-PLGA 50:50 with the exception of the peak at 1671.87 
cm−1 which was available but with decrease intensity and we also experienced a 
decrease in intensity for the peak at 1754.32 cm−1 when compared to the parent 
compounds. 
Overall both physical mixtures showed slight shifts, disappearance, increase and 
decrease in intensity of characteristic peaks when compared to the parent compounds, 
thus indicating an interaction between the TDF and PLGA. A summary of the bands is 
in Table C1.3 in appendix C. 
4.2.2 Hot stage microscopy (HSM) 
The results presented below were obtained during sample analysis using hot stage 
microscopy (HSM). The compounds were analyzed individually (TDF, PLGA 50:50, 
PLGA 85:15) and in combination as a physical mixture of the polymer with TDF (mixed 
by grinding). The samples where heated up to a maximum temperature of 200°C at a 
temperature increase rate of 10°C per min.  
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Figure 4.3(a) shows images of TDF taken during HSM analysis. The melting of TDF 
commenced in the temperature range, 113°C to 118°C. At 120°C, the sample had 
completely melted, and at this temperature, bubbles were noticed. The appearance of 
bubbles could be because of gas (due to sublimation) accumulation between the glass 
slides (cover slide and sample holder). The results obtained from this analysis were in 
line with the certificate of analysis which indicated that the melting point of TDF was 
between 114°C and 118°C. The degradation of TDF started at about 180°C, observed 
by discoloration of the sample. 
 
Figure 4.3: HSM images of (a) TDF, (b) PLGA 50:50, (c) PLGA 85:15, (d) TDF-PLGA 
50:50 physical mixture, and (e) TDF-PLGA 85:15 physical mixture 
The melting of PLGA 50:50 when analyzed using HSM is shown in Figure 4.3(b). 
Melting commenced at about 45°C; the sample gradually melted with no appearance 
of bubbles, an indication that no moisture was entraped in the samples. At 
temperatures above 60°C, the sample had passed its indicated glass transition 
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temperature, and appeared to be oily and viscous. There were however no visible 
signs of degradation (discolouration) even at temperatures up to 200°C. 
Figure 4.3(c) presents HSM analysis of PLGA 85:15, with melting commencing at 
about 55°C. The sample gradually melted with no appearance of bubbles, like what 
was obtained with PLGA 50:50, also an indication that no moisture was entrapped in 
the samples. At temperatures above 60°C, the sample had passed its indicated glass 
transition temperature, and appeared to be oily and viscous. As happened with PLGA 
50:50, the samples did not show any visible signs of degradation even at temperatures 
up to 200°C. 
Figure 4.3(d) shows images from the HSM analysis of the polymer mixture (TDF-PLGA 
50:50). Signs of melting were observed from temperatures around 56°C, with the 
appearance of bubbles at temperature changes between 110°C and 114°C. This was 
around the melting point of the API, confirming the presence of the API in the physical 
mixture. The appearance of the bubbles was also an indication of moisture entrapment 
between the slides covering the sample. The bubbles eventually disappeared, and 
signs of degradation such as browning of the sample appeared at a temperature of 
160°C. 
Figure 4.3(e) presents images from the HSM analysis of TDF-PLGA 85:15 physical 
mixture. Signs of sample melting were observed around 56°C, with the appearance of 
bubbles at temperatures between 110°C and 114°C. This was also around the melting 
point of TDF, confirming its presence in the physical mixture. The appearance of the 
bubbles was an indication of moisture being entrapped between the slides covering 
the sample, or fumes from the API melting. Unlike what was obtained with TDF-PLGA 
50:50 physical mixture [Figure 4.3(d)] however, the bubbles did not disappear on 
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continued heating and instead grew bigger, indicating degradation. Another sign of 
degradation, browning of the sample, appeared at a temperature of 160°C. Given that 
the copolymers, PLGA 50:50 and PLGA 85:15, did not show any signs of degradation 
under HSM analyses [Figure 4.3 (b) and (c)] while TDF did, the presence of TDF in 
the physical mixture can be inferred from the degradation observed on HSM of TDF-
PLGA 85:15. 
4.2.3 Thermogravimetric analysis (TGA)  
Changes in thermal stability, organic solvent evolution and the degradation of TDF, 
PLGA 50:50, PLGA 85:15, and a mixture(physical) of both polymers with TDF (mixed 
by grinding) was evaluated using TGA. Figure 4.4 shows the TGA curves obtained 
when the samples were analyzed. There was release of volatile substance from the 
samples and weight loss due to moisture was observed. The temperature at which 
mass loss began (Tonset°C) and ended (Tendset°C) as well as the temperature at which 
maximum mass loss occurred (Tdeg.max.°C) were determined and are presented in 
Table C1.4 in appendix C. 
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Figure 4.4: TGA curves of (a) PLGA 85:15, (b) TDF-PLGA 50:50 physical  mixture, (c) 
TDF-PLGA 85:15 physical mixture, (d) PLGA 50:50, and (e) TDF. 
Both polymers (PLGA 50:50 and 85:15) displayed two mass loss events associated 
with the degradation process of the polymer [Figure 4.4 (a) and (d)]. PLGA 50:50 had 
a first and second mass loss of about 30% and 68%, respectively, while PLGA 85:15 
showed mass loss values of about 65% and 35%, respectively. When compared to 
each other, PLGA 50:50 did not obtain a 100% mass loss; it proceeded with a 2% inert 
residue. When the physical mixtures of TDF with PLGA 50:50 and TDF with PLGA 
85:15 were analyzed, both samples showed a single mass loss event compared to the 
individual polymers and TDF [Figure 4.4 (b) and (c)]. The percentage mass loss for 
TDF-PLGA 50:50 and TDF-PLGA 85:15 were about 93% and 98%, respectively.  
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The Tonset values for TDF-PLGA 50:50 and TDF-PLGA 85:15 were at a lower 
temperature when compared to that of both polymers and higher than that of TDF 
alone (Table C1.4) in appendix C. The physical mixture of TDF and PLGA showed an 
overall increase in thermal stability when compared to the individual polymers and 
TDF[1]. The differences in the mass loss percentages in the polymers could be 
attributed to their differences in molecular mass and composition since each polymer 
has a different ratio of lactic and glycolic acid. 
4.2.4 Differential Scanning Calorimetry (DSC) 
Prior to formulation of the nanoparticles, the melting points of the samples were 
determined using DSC. Figure 4.5a shows the thermograms of PLGA 50:50 and PLGA 
85:15; both co-polymers showed a single endothermic peak, indicating that the melting 
points for both polymers were at about 55.41°C and 45.84°C, respectively. 
Figure 4.5b shows the DSC thermogram of TDF. Two endothermic peaks were 
observed, within the range of temperatures, 111°C-118°C; these peaks corresponded 
to the melting points of two different polymorphic forms of TDF, according to literature 
there are about three different polymorphic forms (A, B and I).[2,3]  The first endothermic 
peak was because of polymorphic form I-1 melting, which was then followed by 
recrystallisation (an exothermic event) of the melted API into form I which presented 
with a melting peak of 118°C[2,4], thus both endothermic peaks can be attributed to the 
different forms of TDF. 
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(a) 
(b) 
(c) 
Figure 4.5: DSC thermograms of (a) PLGA (50:50 and 85:15), (b) Tenofovir disoproxil 
fumarate, (c) TDF-PLGA 50:50 and TDF-PLGA 85:15 physical mixtures. 
 
Figure 4.5c presents thermograms of TDF when it was analyzed as a physical mixture 
by grinding separately with PLGA 50:50 and PLGA 85:15. A single endothermic event 
was observed for each sample, with highest peaks at 58.27°C and 56.51°C for TDF-
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PLGA 50:50 and TDF PLGA 85:15 physical mixture, respectively. Comparing these 
peaks with PLGA alone, a slight shift of about 3-4°C can be observed. This indicates 
a slight increase in stability of the physical mixture, which might also indicate that there 
is some form of interaction taking place in the physical mixture. 
4.3 Formulation and characterisation of TDF loaded nanoparticles  
Figure 4.6 below shows diagrammatically each step in the formulation of TDF-loaded 
nanoparticles. Formulation was done using the water-in-oil-in-water double emulsion 
solvent evaporation and diffusion method by Liu et al., 2010  with modifications to 
decrease nanoparticle size and increase encapsulation efficiency. 
 
Figure 4.6: Schematic presentation of TDF-loaded nanoparticle formulation process. 
After formulation, the loaded nanoparticles were freeze dried and characterized for 
particle size and distribution, surface morphology, zeta potential, percentage yield, 
drug entrapment and encapsulation efficiency. 
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4.3.1 Particle size and distribution (polydispersity index ) PDI 
The particle size distribution of the TDF-PLGA (50:50 and 85:15) loaded nanoparticles 
was determined immediately after formulation and evaporation of the organic solvents 
from the sample, using dynamic light scattering in the Malvern particle-sizing system. 
The mean particle sizes for TDF-PLGA 50:50 and TDF-PLGA 85:15 were found to be 
117.3 ± 0.45 nm and 103.0 ± 1.62 nm, respectively. There was an increase in particle 
sizes after the TDF-PLGA (50:50 and 85:15) loaded nanoparticles were washed three 
times with distilled water. The average sizes after washing for TDF-PLGA 50:50 and 
TDF-PLGA 85:15 were found to be 153.2 ± 4.3 nm and 127 ± 2.32 nm, respectively. 
The increase in particle size (Table 4.1) could have resulted from particle aggregation 
after the surfactants and emulsifiers had been removed by the washing process.  
Table 4.1: Particle size distribution of TDF-loaded nanoparticles. 
 
The particle size of formulated nanoparticles plays an important role in their 
therapeutic efficacy. The smaller the particle size, the higher the rate of particle 
absorption from the intestine into the blood stream.[5,6] Therefore, a high uptake of 
particles is expected from the formulation prepared, given the particle sizes obtained.  
The postulated mechanisms to show how particles pass through the gastrointestinal 
and physiological barriers highlights endocytosis as one of the mechanisms, for 
particles < 500 nm. It can therefore be seen that the sizes of TDF-PLGA 50:50 and 
TDF-PLGA 85:15 nanoparticles immediately after formulation (117.2 ± 2.33 nm and 
103.0 ± 1.62 nm, respectively) and immediately after washing (153.2 ± 4.3 nm and 
127.0 ± 2.32 nm, respectively) favors uptake via endocytosis. As such, it may be 
Formulated nanoparticle                Particle size (nm)  
Before wash  After wash  
TDF-PLGA 50: 50 117.3 ± 0.45 153.2 ± 4.3 
TDF-PLGA 85: 15 103.0 ± 1.62 127.0 ± 2.32 
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inferred that the formulated nanoparticles would easily permeate physiological barriers 
to promote absorption. 
Table 4.2: Polydispersity index of TDF-loaded nanoparticles. 
Formulated nanoparticle 
    
Polydispersity index 
 
 Before wash  After wash 
TDF-PLGA 50: 50 0.160 ± 0.01  0.303 ± 0.06 
TDF-PLGA 85: 15 0.152 ± 0.04  0.355 ± 0.01 
 
The polydispersity index (PDI) values (Table 4.2) for TDF-PLGA (50:50) and TDF-
PLGA (85:15) after formulation were found to be an average of 0.160 ± 0.01 and 0.152 
±0.07, respectively. These PDI values increased to 0.303 ± 0.06 and 0.355 ± 0.01 
(Table 4.2) for TDF-PLGA 50:50 and TDF-PLGA 85:15, respectively, after washing of 
the loaded nanoparticles. These values are indicative of a homogenous distribution of 
the nanoparticles. PDI values between 0.1 and 0.4 are indicative of monodisperse 
samples; the nanoparticles are relatively of the same size, width and/or shape while 
PDI value greater than 0.5 indicate a polydispersed sample.[7] The increase in the PDI 
after washing of the pellets could be due to such pellets aggregating or coalescing 
after removal (washing) of the surfactants and emulsifiers, hence making the 
distribution a bit more heterogeneous post washing.  
4.3.2 Evaluation of surface morphology of the nanoparticles  
The morphology (shape and properties) of the nanoparticles was determined using 
high resolution scanning electron microscopy (HR-SEM). Blank nanoparticles were 
prepared and the morphology (shape and properties) of the nanoparticles were 
determined. Figure 4.7 [(a) and (b)] shows images of blank PLGA 50:50 and blank 
PLGA 85:15 nanoparticles; the images showed that the particles were spherical in 
shape with smooth surfaces.  
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Figure 4.7c shows images of TDF-PLGA 85:15 loaded nanoparticles. The images 
showed spherical shaped particles with smooth surfaces. The average particle size 
was above 200 nm which was greater than the sizes provided by the zeta sizer (127 
nm). As mentioned previously, the increase in size might be due to aggregation and 
coalescence of the nanoparticles. Such aggregation and coalescence may be 
attributed to the freeze-drying process, which may have caused irreversible fusion of 
the nanoparticles. The freeze-drying process can also cause mechanical stress on the 
nanoparticles leading to a change in particle morphology.[8] As shown by (Pirooznia et 
al., 2012), the addition of cryoprotectants in the final step before lyophilization can 
decrease the tendency for the nanoparticles to aggregate, thus preventing changes in 
particle morphology.  
 
Figure 4.7: HR-SEM of formulated nanoparticles: (a) Blank PLGA 50:50, (b) Blank 
PLGA 85:15, (c) TDF-PLGA 85:15 loaded, (d) TDF-PLGA 50:50 loaded 
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Figure 4.7d shows images of TDF-PLGA 50:50 taken using the HR-SEM. Similar 
characteristics to those which were obtained with TDF-PLGA 85:15 were observed 
(Figure 4.7c); the nanoparticle surface was smooth and spherical, with signs of 
aggregation and coalescence.  
When Figure 4.7a and Figure 4.7b were compared to Figure 4.7c and Figure 4.7d the 
latter appeared to be less smooth and more coagulated this might be as a result of the 
presence of TDF in the formulation.  
4.3.3 Zeta potential  
Following formulation of the TDF-PLGA 50:50 and TDF-PLGA 85:15 loaded 
nanoparticles, their zeta potentials were determined using the Malvern zeta-sizing 
system. The mean zeta potential values for TDF-PLGA 50:50 and TDF-PLGA 85:15 
were found to be -8.84 ± 0.35 mV and -5.69 ± 0.6 mV, respectively (Table 4.3). These 
values decreased to -19.1 ± 0.91 mV and -5.72 ± 1 mV, respectively, after washing of 
the samples. The change in zeta potential for TDF-PLGA 85:15 was not significantly 
different. The negative charge on the nanoparticles directly affects the cellular uptake 
of the nanoparticles by inducing a positive charge on the cell membrane, resulting in 
attraction between the two surfaces. The decrease in the zeta potential values is also 
an indication of the increased stability of the nanoparticles. A high bioavailability may 
be obtained due to this increased stability, because the TDF loaded nanoparticles 
would possibly be able to permeate the cell membrane and be transported to 
endosomes found within the cell.[9] 
 
 
 
http://etd.uwc.ac.za/
Chapter 4: Results and discussion of TDF PLGA nanoparticle 
77 
 
Table 4.3: Zeta potential of TDF-loaded nanoparticles 
Drug Polymer ratio Zeta potential 
Before wash After wash 
TDF-PLGA 50: 50 -8.84 ± 0.35 mV -19.1 ±0.91 mV 
TDF-PLGA 85: 15 -5.69 ± 0.6 mV -5.72 ± 1 mV 
 
4.3.4 Percentage yield  
The percentage yield is the total amount of nanoparticles recovered after formulation 
expressed as a percentage of the total weight of products used for formulation, while 
drug entrapment efficiency is the ratio of the API amount expected to be loaded versus 
the actual amount of API loaded after formulation and encapsulation efficiency 
determines the actual amount of drug found in the formulated nanoparticles. 
TDF-PLGA 50:50 and TDF-PLGA 85:15 loaded nanoparticles were recovered and 
weighed after freeze-drying. The values obtained after weighing were 71.2 mg and 
61.0 mg, for TDF-PLGA 50:50 and TDF-PLGA 85:15 loaded nanoparticles, 
respectively (Table 4.4). The percentage yield was calculated as per Equation 3.2  
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑦𝑖𝑒𝑙𝑑(%) =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑃𝐿𝐺𝐴, 𝑑𝑟𝑢𝑔 𝑎𝑛𝑑 𝑒𝑥𝑐𝑖𝑝𝑖𝑒𝑛𝑡𝑠
 𝑢𝑠𝑒𝑑 𝑖𝑛 𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 
𝑥100 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑦𝑖𝑒𝑙𝑑(%) =
71.2 𝑚𝑔 
105 𝑚𝑔
𝑥100 
            = 67.82% for TDF-PLGA 50:50 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑦𝑖𝑒𝑙𝑑(%) =
61 𝑚𝑔 
105 𝑚𝑔
𝑥100 
            = 58.10% for TDF-PLGA 85:15 
The percentage yield was calculated to be 67.82% and 58.10% for TDF-PLGA 50:50 
and TDF-PLGA 85:15 loaded nanoparticles, respectively. The loss in mass could be 
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due to unbound polymer and drug discarded during collection of the formulated 
nanoparticles or washing process. 
 Table 4.4: Mass of TDF-loaded nanoparticles recovered (mg) and percentage yield. 
Drug polymer 
combination 
Mass of TDF 
used in 
formulation(mg) 
Mass of 
polymer 
used (mg) 
Mass of 
nanoparticle 
recovered 
(mg) 
Percentage 
yield (%) 
TDF-PLGA 50:50 5 100 71.2 67.82 
TDF-PLGA 85:15 5 100 61 58.10 
To determine the encapsulation efficiency and entrapment, we first needed to 
develop a method (HPLC-DAD and UV-spectrometry method) of which we used to 
determine the amount of TDF in the nanoparticles. 
4.3.5 Standard calibration plot for determination of TDF (HPLC-DAD and UV-
spectrometry method) 
To determine linearity of the method, samples were analyzed at an absorbance 
frequency of 260 nm, at which TDF is reported to have its maximum absorbance. [10] A 
linear regression model was used to study the relationship between absorbance of 
TDF and its concentration, and a graph of mean TDF absorbance versus TDF 
concentration was plotted (Figure 4.8). This model enabled the prediction of TDF 
concentration in the prepared nano-formulations by measuring its absorbance in the 
sample; data obtained is featured in appendix C (Table C1.1 and Table C1.2). 
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Figure 4.8: Standard calibration graph of Tenofovir disoproxil fumarate 
(λmax=260nm).  
Stock solutions and working standards were prepared in phosphate buffer solution 
(PBS) at a pH of 1.2 and pH 7.4. Samples were analyzed at 25ºC. Data values were 
recorded in triplicate presented as mean ± SD (n=3). 
Table 4.5 presents computed data derived from plotting the calibration curves for TDF. 
The R2 values at pH 1.2 and pH 7.4 depicted linearity and showed how close the data 
was to the fitted regression line. The relationship between concentration and 
absorbance can be expressed by Equation 4.1 with substitutions from Table 4.5. From 
this, the amount of drug encapsulated within the nanoparticles was determined. Data 
obtained is featured in appendix C (Table C1.1 and Table C1.2). 
𝑦 =  𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 + 𝑠𝑙𝑜𝑝𝑒(𝑥) 
Equation 4.1 
where  y = TDF peak area  
                     x  = the standard solution concentration in µg/ml  
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Table 4.5: Linearity data and quantification limits of Tenofovir disoproxil fumarate at 
pH 1.2 and 7.4 (HPLC-DAD and UV-spectrometry methods).  
Validation 
parameters  
HPLC-DAD  UV-spectrometry 
 pH 1.2  pH 7.4 pH 1.2 pH 7.4 
R2 0.9781 0.9999 0.9702 0.9938 
Slope ± SD 3578.54±69.44 1677.96±7.86 0.0220±0.002 0.02±0.001 
Intercept ± SD 0.32±5.01 0.79±0.567 0.024±0.01 -0.002±0.01 
Concentration 
range (µg/ml) 
0.02-0.12 0.02-0.12 200-1200 200-1200 
LOD (µg/ml) 0.001 0.01 1.87 0.85 
LOQ (µg/ml) 0.003 0.014 5.65 2.5 
 
Analyses with HPLC-DAD presented better linearity values than those with UV-
spectrometry, and linearity values obtained at pH 7.4 seemed better than values 
obtained at pH 1.2 (as shown by the R2 values); however, it is not clear if these 
differences in values are statistically significant. The results obtained indicate that the 
two methods, HPLC-DAD and UV-spectrometry, were sensitive enough to determine 
the concentration of the API in the standard solutions. However, the concentration 
ranges, as well as the LOD and LOQ values are lower for the HPLC-DAD method than 
for the UV-spectrometry method, attesting to the increased sensitivity of the HPLC-
DAD compared to the UV-spectrometry method. 
The percentage recovery was calculated from the equation of the calibration curve 
and was found to be between 98% and 102% (Table 4.6). This was acceptable when 
viewed against the International Conference on Harmonisation (ICH) guidelines for 
assays using the HPLC-DAD method. The precision (repeatability) of the methods was 
determined by analyzing replicates of TDF standard solution, at three different 
concentrations (over the ranges, 0.02-0.12 μg/μl for the HPLC-DAD method and 2-12 
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μg/μl for the UV-spectrometry method) covering the standard calibration range (Table 
C1.1 and Table C1.2 in the appendix ). The values were expressed as % RSD and 
found to be less than 2% (Table 4.6); suggesting that the results provided by the 
methods are reproducible.  
Table 4.6: Intra-day and inter-day assay precision and accuracy for Tenofovir 
disoproxil fumarate at pH 1.2 and 7.4 (HPLC-DAD method). 
              pH 1.2                 pH 7.4 
TDF(μg/μl) 0.02 0.06 0.12  0.02 0.06 0.12 
 Intra-day (n=3) 
                    Day 1 
Mean  0.02 0.06 0.12  0.02 0.06 0.12 
SD 0.0003 0.0009 0.0006  0.0003 0.0008 0.0007 
Precision1 (%) 1.51 1.51 0.51  2.01 1.32 0.59 
Accuracy2 (%) 99.50 99.30 97.92  99.50 100.80 99.40 
              Day 2 
Mean  0.02 0.06 0.12  0.02 0.06 0.12 
SD 0.0002 0.0007 0.0012  0.0002 0.0007 0.0005 
Precision1 (%) 1.00 1.17 1.02  1.00 1.13 0.42 
Accuracy2 (%) 100.00 99.83 98.00  99.50 101.80 99.10 
                  Day 3 
Mean  0.02 0.06 0.12  0.02 0.06 0.12 
SD 0.0002 0.0006 0.0009  0.0003 0.0009 0.0009 
Precision1 (%) 1.00 1.00 0.77  1.47 1.50 0.75 
Accuracy2 (%) 100.50 99.50 97.83  99.50 99.50 99.50 
   Inter-day (n=9) 
Mean3 0.02 0.06 0.12  0.02 0.06 0.12 
SD 0.00008 0.0001 0.00008  0.0002 0.0008 0.0002 
Precision1 (%) 0.40 0.12 0.07  1.00 1.32 0.17 
Accuracy2 (%) 100.00 99.50 97.92  100.50 101.00 99.30 
 
The accuracy of the method for assay purposes was determined by measuring the 
absorbance of TDF at three different concentrations (0.02, 0.06, 0.12 μg/ μl and 2, 6, 
12 μg/ μl, for the HPLC-DAD and UV-spectrometry methods, respectively) covering 
the standard calibration range (Figure 4.8). The accuracy data from the UV-
spectrometry method on the other hand provided values within the range, 99-116.7% 
(Table 4.7). The acceptable recovery range in assays for quality control and drug 
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registration is between 90 and 110%,[11] and so this method did not meet the 
requirements for quality control and drug registration. However, since this study is still 
preliminary and not for quality control or drug registration purposes, the UV 
spectrometry method was also utilized as a comparison to the HPLC-DAD method for 
determination of TDF in samples. 
Table 4.7: Intra-day and inter-day assay precision and accuracy for Tenofovir 
disoproxil fumarate at pH 1.2 and 7.4 (UV-spectrometry method). 
 pH 1.2 pH 7.4 
TDF(μg/μl) 2 6 12  2 6 12 
 Intra-day (n=3) 
              Day 1 
Mean  2.04 6.90 11.63  1.98 5.95  12.03 
SD 0.0006 0.0008 0.0006  0.0002 0.0003 0.0007 
Precision1 (%) 0.03 0.01 0.005  0.08 0.005 0.006 
Accuracy2 (%) 102 115 96.9  99 99.2 100.3 
              Day 2 
Mean  2.05 6.87 11.52  2.07 6.01 12.19 
SD 0.0005 0.0013 0.0020  0.0003 0.0001 0.0002 
Precision1 (%) 0.02 0.02 0.02  0.01 0.002 0.002 
Accuracy2 (%) 102.5 114.5 96.0  103.5 100.1 101.6 
              Day 3 
Mean  2.04 7.00 11.57  2.09 6.05 12.01 
SD 0.0006 0.0006 0.0025  0.0002 0.0001 0.0002 
Precision1 (%) 0.030 0.009 0.020  0.010 0.002 0.002 
Accuracy2 (%) 100.1 116.7 96.4  104.5 100.8 102.0 
                                                      Inter-day (n=9) 
Mean3 2.04 6.92 11.68  2.07 6.00 12.15 
SD 0.0002 0.0020 0.0010  0.0005 0.0010 0.0020 
Precision1 (%) 0.01 0.03 0.90  0.02 0.02 0.02 
Accuracy2 (%) 102.00 115.30 97.30  103.50 100.00 101.30 
 
Values obtained in Table 4.6 and Table 4.7 were calculated as follows;  
❖ 1Expressed as % RSD = (SD/mean) × 100. 
❖ 2Calculated as (mean determined concentration/nominal concentration) × 100. 
❖ 3n = 3 days with three replicates per day 
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4.3.6 Encapsulation efficiency  
The encapsulation efficiency was determined using Equation 3.6.  
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦(%)   
=   
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑡ℎ𝑒 𝑦𝑖𝑒𝑙𝑑 
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑 𝑑𝑢𝑟𝑖𝑛𝑔 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 
𝑥100 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦(%)   =   
2.29
5
𝑥100 
                                 = 45.8% for TDF-PLGA 50:50 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦(%)   =   
2.49
5 
𝑥100 
                                 = 49.8 for TDF-PLGA 85:15 
The total amount of drug in the yield was determined by dissolving 5 mg of the TDF-
loaded nanoparticles in 0.5 ml of ethyl acetate (in a 5 ml Eppendorf tube) with 
vortexing. The ethyl acetate was evaporated, and 3 ml of phosphate buffer solution 
(PBS) was added to the Eppendorf tube. The tube was vortexed, and the contents 
centrifuged at a speed of 10000 rpm for 15 minutes. Thereafter, the supernatant was 
collected, and the absorbance measured using the UV-spectrometer and HPLC-DAD 
system. The concentration of the drug in that sample was determined by extrapolating 
the absorbance value from the calibration plot of TDF in Figure 4.8. 
The results obtained from using Equation 3.6 are presented in Table 4.8. The nano-
formulations prepared with PLGA 85:15 showed about 4% increase in drug 
encapsulation when compared to those prepared with PLGA 50:50. The significance 
of this difference was however not calculated. A possible reason for this could be the 
high ratio of PLA (hydrophilic nature) in the PLGA 85:15 polymer. The encapsulation 
efficiency suggests that less than half the initial amount of TDF used during the 
formulation process was recovered after formulation. The amount of TDF lost might 
be because of un-encapsulated drug discarded during the washing process. 
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Table 4.8: Total amount of drug in recovered TDF-loaded nanoparticles and 
encapsulation efficiency. 
Drug polymer 
combination  
Amount of drug in 
nano-formulation (mg) 
Encapsulation efficiency (%) 
TDF-PLGA 50:50 2.29 45.8 
TDF-PLGA 85:15 2.49  49.8 
4.3.7 Drug entrapment efficiency 
The theoretical drug loading, actual drug loading, and drug entrapment efficiency, 
were calculated using the following equations  
 Equation 3.3,  
 𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (𝑇𝐷𝐿)(%) =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑 
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 𝑎𝑛𝑑 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑 
𝑥 100 
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (𝑇𝐷𝐿)(%) =
5
105 
𝑥 100 
                                         = 4.76% for both TDF-PLGA 50:50 and 85:15 
 Equation 3.4, 
𝐴𝑐𝑡𝑢𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (%) =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
𝑥100 
𝐴𝑐𝑡𝑢𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (%) =
2.29 
71.2
𝑥100 
= 3.23% for TDF for PLGA 50:50 
𝐴𝑐𝑡𝑢𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (%) =
2.49 
61 
𝑥100 
  = 4.08% for TDF for PLGA 85:15 
and Equation 3.5; 
𝐷𝑟𝑢𝑔 𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦(%) =
𝑎𝑐𝑡𝑢𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 
𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 
𝑥100 
𝐷𝑟𝑢𝑔 𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦(%) =
3.23 
4.76 
𝑥100 
                                                                                  = 67.86% for TDF-PLGA 50:50 
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𝐷𝑟𝑢𝑔 𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦(%) =
4.08
4.76 
𝑥100 
                                                                                    = 85.71% for TDF-PLGA 85:15 
Table 4.9 presents the results of the calculations. The formulation with PLGA 50:50 
had a higher entrapment efficiency of the drug (TDF) than the formulation with PLGA 
85:15. The reasons for the difference in entrapment efficiency are yet unknown, our 
hypothesis is that this might be as a result of differences in the polymer ratios. The 
significance of this difference was however not calculated.  
Table 4.9: Actual and theoretical drug loading values, and drug entrapment efficiency 
of TDF-PLGA formulations 
Drug/polymer 
combination 
Theoretical 
drug loading 
(% w/w) 
Actual drug 
loading (% w/w) 
Drug entrapment 
efficiency (% w/w) 
TDF-PLGA 50:50 4.76 3.23 67.86 
TDF-PLGA 85:15 4.76  4.08 85.71 
 
4.3.8 Fourier Transform Infrared Spectroscopy (FT-IR) 
Following drug loading, the nanoparticles were analyzed using FT-IR spectroscopy. 
Figure 4.9 presents the FT-IR spectra of TDF-PLGA (50:50) and TDF-PLGA (85:15) 
physical mixtures and loaded nanoparticles. When compared to the FT-IR spectra 
obtained during analysis of the parent compounds and the physical mixtures, the 
characteristic intensity bands, that is the peaks obtained with the loaded products 
mostly corresponded to the polymer (PLGA 50:50 or 85:15) Figure 4.2 a & c. From 
this, it can be inferred that TDF was encapsulated within the polymer. Comparison of 
both loaded polymers (loaded formulations of PLGA 50:50 and 85:15) showed the 
appearance of an extra intensity peak at 2945.29 cm-1 (Figure 4.9d) for TDF-PLGA 
85:15 loaded nanoparticles, which was not observed with the TDF-PLGA 50:50 loaded 
nanoparticles (Figure 4.9c) or the physical mixture of TDF-PLGA 85:15. TDF-PLGA 
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85:15 also presented with the disappearance of a peak at 1674.85 cm-1 present in the 
physical mixture but absent in TDF-PLGA 85:15 loaded nanoparticles, indicating that 
there is some interaction taking place between the two components . This also further 
confirmed that TDF was indeed encapsulated within the polymer. Figure 4.10 below 
shows possible points of interactions between PLGA and TDF. 
The differences shown in the FT-IR spectra of both polymers could be due to their 
ratios, that is, their composition and molecular weight. Comparing TDF-polymer 
physical mixture to TDF-PLGA loaded nanoparticles, it was noted that the frequency 
band values for TDF-PLGA loaded nanoparticles had increased; further confirming an 
interaction (hydrogen bonding) between TDF and PLGA (Table 4.10). This interaction 
is possibly an encapsulation of TDF within the polymer. It is known that the 
physicochemical properties of PLGA enable it to entrap drugs for onward delivery to 
the required site of action[12]. As such, evidence of TDF encapsulation within the 
polymer may infer a possible improvement in TDF delivery. 
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Table 4.10: Selected FTIR data for TDF-PLGA 50:50 and TDF-PLGA 85:15 loaded 
nanoparticles compared with TDF-PLGA 50:50 physical mixture and TDF-PLGA 
85:15 physical mixture. 
Analyzed 
sample 
Experimental 
frequency 
bands (cm-1) 
Standard 
frequency 
bands (cm-1) 
Associated functional 
groups from IR bands  
TDF-PLGA 50:50 
loaded 
2949.09 3000 - 2500 Chelated O-H stretching 
bridge 
1748.08 1790 - 1740 Strong C=O stretching of the 
carbonyl group 
TDF-PLGA 85:15 
loaded 
2995.67 3000 - 2500  Chelated O-H stretching 
bridge 
2945.29 3000 - 2500  Chelated O-H stretching 
bridge 
1748.18 1790 - 1740 Strong C=O stretching of the 
carbonyl group 
TDF-PLGA 50:50 
physical mixture  
2993.81 3000 - 2500  Chelated O-H stretching 
bridge 
1750.07 1790 - 1740 Strong C=O stretching of the 
carbonyl group 
TDF-PLGA 85:15 
physical mixture  
2985.88 3000 - 2500  Chelated O-H stretching 
bridge 
1754.32 1790 - 1740 Strong C=O stretching of the 
carbonyl group 
1674.85 1685 - 1665 Strong C=0 stretching 
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Figure 4.9: FT-IR spectra of (a): TDF-PLGA 50:50 physical mixture, (b): TDF-PLGA 
85:15 physical mixture(c): TDF-PLGA 50:50 loaded and (d): TDF-PLGA 85:15 loaded 
nanoparticles. 
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Figure 4.10: Schematic representation of possible functional group interactions 
between TDF and PLGA.  
4.3.9 Hot Stage Microscopy (HSM)  
Following collection of the freeze dried TDF-loaded nanoparticles, the samples were 
analyzed using HSM. Figure 4.11c shows images from the HSM analysis of TDF-
PLGA 50:50 loaded nanoparticles.  
Changes to the sample because of an increase in temperature were a bit difficult to 
visualize between 40°C and 60°C; however noticeable changes such as signs of 
melting were observed at temperatures above 110°C. No appearance of bubbles or 
visible degradation of the sample was observed. This could be explained by the 
rationale that the polymer completely encapsulated TDF and therefore protected it 
from degradation. It may also be because the amount of TDF in the formulation was 
too small for the degradation process to be visualized. 
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Figure 4.11: HSM images of TDF-PLGA 50:50 physical mixture, TDF-PLGA 85:15 
physical mixture, TDF-PLGA 50:50 loaded, and TDF-PLGA 85:15 loaded 
nanoparticles. 
Both TDF loaded nanoparticles and physical mixtures showed an increase in thermal 
stability (Figure 4.11) when compared to the parent compounds. A reference to Figure 
4.11c shows that the HSM of TDF-PLGA 50:50 loaded nanoparticles did not show any 
evidence of being oily or viscous, but rather appeared to dry up at temperatures above 
130°C.  Figure 4.11d shows images from the HSM of TDF-PLGA 85:15 loaded 
nanoparticles. Changes to the sample with increase in temperature were a bit difficult 
to visualize at temperatures between 40°C and 60°C, as was the case with TDF-PLGA 
50:50 loaded nanopartilces, with the sample showing signs of melting at temperatures 
above 110°C. unlike what was observed with Figure 4.11c, the TDF-PLGA 85:15 
sample (Figure 4.11d) appeared to be oily and viscous at temperatures above 130°C. 
This may be because of the difference in polymer ratios used. No appearance of 
bubbles or visible degradation of the sample was observed on continued heating of 
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TDF-PLGA 85:15. As with TDF-PLGA 50:50, this could be explained by the rationale 
that the polymer completely encapsulated TDF and therefore protected it from 
degradation, or that the amount of TDF in the formulation was too small for the 
degradation process to be visualized. If the former is the case, then the oral delivery 
of TDF would likely be improved by its encapsulation within the polymer. (NB melting 
point of TDF is in the range 114-118 °C). 
4.3.10 Thermogravimetric analysis (TGA) 
Thermogravimetric data analysis of TDF-PLGA (50:50 and 85:15) loaded 
nanoparticles (Figure 4.12) shows the exhibition of two mass loss events. This was 
different when compared to the single mass loss event exhibited by the TDF-PLGA 
physical mixtures (Figure 4.4c). The differences in the TGA results between the 
physical mixture and the nano-formulation could perhaps be a result of change in 
thermal stability of the nano-formulation.  
 
Figure 4.12: TGA curve of (a) TDF-PLGA 50:50 loaded and (b) TDF-PLGA 85:15 
loaded nanoparticles. 
Table C1.5 in the appendix presents data from the thermal analyses of TDF formulated 
nanoparticles. This shows the temperatures at which sample degradation started, and 
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when degradation ended. The results indicated that TDF-PLGA 50:50 and TDF-PLGA 
85:15 exhibited a total mass loss of about 93 and 91%, with a 7% and 9% inert residue 
remaining, respectively.  
4.3.11 Differential Scanning Calorimetry (DSC) 
Figure 4.13 below shows thermograms of TDF-PLGA 50:50 and TDF-PLGA 85:15 
loaded nanoparticles. No identifiable peaks of TDF could be found in the thermograms. 
This could indicate that no crystalline TDF was found in the nanoparticles. It may also 
indicate that TDF was molecularly dispersed in the polymer matrix, or that the amount 
of TDF present in the analyzed sample was too small to show any significant peaks. 
The loaded nanoparticles however showed peaks that agreed with TDF-PLGA 
physical mixtures (mentioned earlier); that is, it showed melting points of about 
56.38°C and 58.88°C for TDF-PLGA 85:15 and TDF-PLGA 50:50. It is however not 
known if these differences in temperature are significant. 
 
Figure 4.13: DSC thermograms of TDF-PLGA 50:50 and TDF-PLGA 85:15 loaded 
nanoparticles 
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4.3.12 Determination of TDF release from TDF-PLGA loaded nanoparticles  
Figure 4.14 shows the cumulative percentage of drug released from TDF-loaded 
nanoparticles at pH 1.2 and pH 7.4 versus time. Samples were analyzed using HPLC-
DAD and UV-spectrometry. The release profile displayed by both polymers was 
biphasic; an initial burst of TDF accompanied by a sustained release profile as is 
commonly seen in core-shell type nanoparticles[13]. This model also confirmed the 
presence of surface drug on the nanoparticles with the bulk of the TDF encapsulated 
within the nanoparticles. If this is the case, some level of extended release can be 
obtained from the nano-formulation without compromise of immediate release. This 
ensures that the surface drug can be immediately released and delivered to the site 
of action immediately. This will be followed by gradual release of TDF from the nano-
formulation over time, ensuring extending TDF release. 
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Figure 4.14: In-vitro release of TDF-PLGA 50:50 and TDF-PLGA 85:15 loaded 
nanoparticles  
The release was done at pH 1.2 (Figure 4.14a & c) and pH 7.4 (Figure 4.14b & d) at 
37˚C over a period of 48h, analyzed using UV-spectrometry (Figure 4.14a & b) and 
HPLC-DAD (Figure 4.14c & d). Data was collected in triplicates and is here presented 
as mean ± SD (n=3). 
Table 4.11 shows the total percentage of TDF released in 12 hours from the 
formulations. The same sample was analyzed using two analytical methods (HPLC-
DAD and UV-spectrometry). The results from HPLC-DAD analysis, compared to those 
from UV spectrometry, showed additional release of TDF from the formulations at both 
pH values. While human error may be a factor, the low values may very likely be due 
to the lower sensitivity of the UV-spectrometric method. 
 Table 4.11: Percentage of TDF released from formulations after 12 hours analysis 
Formulation Percentage of TDF released 
 
 
HPLC-DAD UV-spectrometry  
pH 1.2 pH 7.4 pH 1.2 pH 7.4  
TDF-PLGA 50:50 63.9% 84.4% 39.82% 47.3%  
TDF-PLGA 85:15 70.9% 93.7% 38.62% 37.64%  
 
4.3.13 Mathematical modeling of drug release data  
The mechanism of TDF release from TDF-PLGA formulated nanoparticles was 
evaluated by fitting the release data to four mathematical models namely; Gompertz 
model, Korsmeyer-Peppas model, Peppas-Sahlin model, and the Weibull model. 
DDsolver a peer-reviewed modelling program[14] was used for this analysis, the 
release data was fitted to the four mathematical models (named above) which are 
commonly used in literature.[15]  
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Best fit model was selected using the adjusted coefficient of determination (R² adj) 
and a model with the highest R² adj was deemed to be the best fit model. R² adj allows 
for better comparison of the models when compared to coefficient of determination 
(R2).[14]  The release data of TDF obtained at both pH 1.2 and 7.4 was fitted to the four 
models mentioned above. Of these four models, the Weibull model was adjudged the 
model of best fit according to the R² adj value obtained, as illustrated in Table 4.12. 
In the Weibull models α is a parameter that represents the time scale, Ti is the lag 
time before onset of the dissolution and β describes the shape of the curve which can 
follow either one of the following: 
• β=1 the shape is exponential  
• β>1 the shape is S-shaped (sigmoid) with an upward curvature followed by a 
turning point. 
• β<1 the shape has a high initial slope followed by a consistent exponential 
curve. 
The Weibull model has four different modifications that generally differ in terms of the 
absence or presence of the following parameters Fmax and Ti. β according to literature 
which can be used as an indicator to describe the mechanism of drug release from a 
polymer matrix.[16] 
Data collected from the different models can be seen in Table 4.12, the Weibull model 
as earlier mentioned was selected as best fit model for the four samples analyzed. 
The value of β was less than 0.75 for all four formulations thereby conforming that the 
release was Fickian diffusion which was in line with data from literature.[16] 
Release mechanism from polymeric systems using Weibull model can be interpreted 
as follows:  
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Time exponent  Release mechanism  
β≤0.75 Fickian diffusion in fractal or Euclidian 
spaces 
0.75<β<1 Combined release mechanism 
β>1 Complex release mechanism 
Table 4.12: Parameter values and R2 adj values obtained from fitting drug release 
experimental data to four mathematical models 
pH   1.2 7.4  
 Parameters  TDF-
PLGA50:50 
TDF-
PLGA85:15 
TDF-
PLGA50:50 
TDF-
PLGA85:15 
Weibull_1  β 0.08 0.01 0.19 0.12 
α 1.01 1.19 0.63 0.75 
Ti 0.5 0.5 0.49 0.5 
R2adj 0.993 0.998 0.994* 0.991 
Gompertz_1 α 0.64 0.71 0.39 0.50 
β 0.56 0.42 1.71 1.01 
R2adj 0.931 0.951 0.983 0.952 
Peppas-
Sahlin_1 
K1 67.24 63.24 86.5 77.78 
K2 -15.20 -14.94 -19.3 -17.01 
m 0.27 0.24 0.27 0.28 
R2adj 0.950 0.964 0.965 0.951 
Korsmeyer-
Peppas with 
Tlag 
n 0.04 0.04 0.04 0.04 
k 63.2 56.8 80.9 74.4 
R2adj 0.992 0.997 0.989 0.988 
 
4.3.14 Stability of TDF-PLGA loaded nanoparticles  
The formulated nanoparticles were stored at temperatures between 2 and 8°C. They 
were evaluated for stability by measuring parameters such as the zeta potential, 
particle size and PDI, at the time of preparation and at different time intervals during 
storage over a period of 90 days. 
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Particle size  
After formulation, the average size of the formulated TDF-PLGA 50:50 nanoparticles 
was measured to be 117.2 ± 2.33 nm while TDF-PLGA 85:15 was measured to be 
111.1 ± 0.02 nm. These values increased to 161.2 ± 4.82 nm and 138.3 ± 0.02 nm 
after washing, then to 2074 ± 63.3 nm and 1824 ± 70.02 nm after freeze drying for 
TDF-PLGA 50:50 and TDF-PLGA 85:15 respectively, with no significant difference 
between the means (p<0.0001). Subsequently, the size increased steadily to about 
4520 ± 93.1 nm and 5598 ± 82.7 nm after 90 days (Figure 4.15). 
N
a
n
o
-p
a
r
ti
c
le
 s
iz
e
 (
n
m
)
A
ft
e
r  
fo
rm
u
la
t i
o
n
 
A
ft
e
r  
w
a
s
h
in
g
 
A
ft
e
r  
f r
e
e
z
e
 d
ry
in
g
1
0
 d
a
y
s
 l
a
te
r
2
0
 d
a
y
s
 l
a
te
r  
3
0
 d
a
y
s
 l
a
te
r  
6
0
 d
a
y
s
 l
a
te
r  
9
0
 d
a
y
s
 l
a
te
r  
0
2 0 0 0
4 0 0 0
6 0 0 0
T D F -P L G A  8 5 :1 5  lo a d e d  n a n o p a rtic le s
D u ra tio n  o f s to ra g e  (d a y s ) T D F -P L G A   lo a d e d  n a n o p a rt ic le s
T D F -P L G A  5 0 :5 0  lo a d e d  n a n o p a rtic le s
 
Figure 4.15: Changes in nanoparticle size of TDF-PLGA 50:50 and 85:15 freeze dried 
loaded nanoparticles 
Comparing both formulations, the particles sizes of TDF-PLGA 50:50 formulations 
were less than those of TDF-PLGA 85:15, at every measurement. The two 
formulations showed the same trend, an increase in particle size that was proportional 
(perhaps not necessarily directly) to the duration of storage. 
The postulated mechanisms to show how particles pass through the gastrointestinal 
and physiological barriers highlights endocytosis as one of the mechanisms, for 
particles < 500 nm. It can therefore be seen that the nanoparticle sizes immediately 
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after formulation and after washing favors uptake via endocytosis. Following the 
freeze-drying and 90-days storage processes however, the increase in particle size as 
mentioned above was such that endocytosis may not be favorable as an uptake 
mechanism. There may however be some success with uptake via lymphatic passage, 
with absorption by cells in Peyer’s patches, especially for particles less than 5 µm. It 
can be seen that the nanoparticle size increased after the washing process, possibly 
due to agglomeration of these particles. We propose that more assessments can be 
carried out to assess ways to limit such agglomeration in the washing process, 
perhaps by the use of suitable surface-active agents. Such an intervention may slow / 
prevent agglomeration, ensuring that particle sizes remain close to the values obtained 
immediately after formulation. This will enhance penetration through physiological 
barriers and hence improve bioavailability.  
Zeta potential  
The average zeta potential of the formulated nanoparticles was also assessed and 
found to be -6.74 ± 0.02 mV and -5.32 ±4.1 mV for TDF-PLGA 50:50 and TDF-PLGA 
85:15 respectively (Figure 4.16), the zeta potential values further decreased after 
washing and freeze drying, indicating an increase in stability. On assessing the 
samples after 10 days of storage, the zeta potential had increased, indicating a 
decrease in stability of the nano-formulation with increase in time. However, on day 
30, the samples showed some discrepancy indicating an increase in stability. The zeta 
potential further increased from day 60 through 90 Figure 4.16, indicating a decrease 
in stability. 
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Figure 4.16: Changes in zeta potential of TDF-PLGA 50:50 and 85:15 freeze dried 
loaded nanoparticles 
Comparing the stability of both formulations, the data indicated that TDF-PLGA 50:50 
seemed more stable than TDF-PLGA 85:15, until day 20 when TDF-PLGA 85:15 
seemed to be more stable than TDF-PLGA 50:50 until day 90. It may not be easy to 
tell at this point, without further studies, if these seeming differences in stability are 
significant – statistically, pharmaceutically, physiologically or therapeutically. 
Polydispersity index  
The PDI of the formulated nanoparticles were also assessed immediately and the 
values were 0.149 ± 1.3 and 0.191 ±3.1 for TDF-PLGA 50:50 and TDF-PLGA 85:15 
respectively. The PDI value further increased which indicated coalescence of the 
nanoparticles after washing and freeze drying (Figure 4.17). The PDI value after day 
10 of storage showed signs of increased coalescence of the nanoparticles. A steady 
increase in the PDI values was expected; however, on day 10, 20 and 30, and 90 for 
both formulations, a decrease in the PDI values was noticed, indicating less 
coalescence, and an increase was noticed in these values from day 60 to 90 (Figure 
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4.17). These changes could be due to more samples aggregating during this period of 
storage. 
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Figure 4.17: Changes in PDI of TDF-PLGA 50:50 and 85:15 freeze dried loaded 
nanoparticles 
Comparing both formulations from the data presented, it could be inferred that TDF-
PLGA 50:50 was more monodispersed than TDF-PLGA 85:15 after formulation until 
day 10 when TDF-PLGA 85:15 became more monodispersed. It is our hypothesis that 
the molecular weight and copolymer ratios may be a factor for these differences. 
The overall changes in the nanoparticle size, zeta potential and PDI over the duration 
of storage were indicative of a decrease in stability of the formulated nanoparticles 
over time.  
Comparing the results obtained from characterizing TDF-loaded nanoparticles with 
other studies we observed that the encapsulation efficiency was less than that 
obtained by Shailender et al., 2017 and Destache et al., 2016 64% and 52.9%, 
respectively. However, the particle size range obtained for this study was less than 
that obtained by the aforementioned studies, with zeta potential higher than that 
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reported by Shailender et al., 2017 (-4.8 mv) but less than what Destache et al., 2016 
(-26.7 mv) reported. Shailender et al., 2017 reported a biphasic release profile which 
was similar to what we obtained with this study. Shailender et al., 2017 also reported 
that the nanoparticles were stable after 3 months of storage between 2 and 8°C, which 
was the opposite of what we obtained. 
Chapter 5 will follow with the results obtained during formulation and characterization 
of nanoparticles formulated with AZT, PLGA 50:50 and PLGA 85:15. 
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CHAPTER 5: RESULTS AND DISCUSSION FOR ZIDOVUDINE LOADED 
NANOPARTICLES  
This chapter presents the results obtained and discussion following when Zidovudine 
(AZT) was analyzed. Emphasis is placed on the different ratios of poly-lactic-co-
glycolic acid (PLGA 50:50 and 85:15) used in this study.  
5.1 Introduction  
The objectives of this study were twofold of which the formulation of AZT as a 
nanoparticle presented the following specific sub-objectives: 
❖ to characterize AZT and PLGA 
❖ to formulate non-covalent complexes of AZT with PLGA of different ratios 
(50:50 and 85:15); 
❖ to characterize and compare physicochemical properties of the formulated 
complexes using various analytical techniques;  
❖ to compare the pharmaceutical properties (i.e. particle size, stability and in-vitro 
release) of both formulations (AZT-PLGA 50:50 and AZT-PLGA 85:15) as a 
means of addressing some of the limitations associated with optimal delivery of 
AZT (e.g., short plasma half-life and extensive first pass metabolism).  
5.2 Characterization of AZT and PLGA (50:50 and 85:15) 
Prior to formulation of the nanoparticle proper, AZT and two PLGA ratios (PLGA 50:50 
and PLGA 85:15) were characterized individually, and in combination as a physical 
mixture (AZT-PLGA 50:50 and AZT-PLGA 85:15). The results of the characterization 
assessments were as follows;  
5.2.1 Fourier-transform infra-red (FT-IR) spectroscopy  
Figure 5.1 below shows the structure of AZT and PLGA while Figure 5.2 shows the 
FT-IR spectra of AZT, PLGA (50:50, and 85:15), and AZT-PLGA (50:50 and 85:15) 
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physical mixtures. The physical mixtures were prepared in a similar manner as 
discussed in chapter 4 section 4.2.1. The FTIR spectra of these physical mixtures were 
compared to those of the single component compounds (AZT, PLGA 50:50 and PLGA 
85:15) to identify characteristic functional groups as a physical mixture, as well as the 
appearance of or disappearance of such functional groups in the combination (Figure 
5.2 and Table 5.1). 
Table 5.1: Selected FTIR data for AZT, PLGA (50:50 and 85:15), AZT-PLGA 50:50 
physical mixture, and AZT-PLGA 85:15 physical mixture 
Analyzed 
sample 
Experimental 
frequency 
bands (cm-1) 
Standard 
frequency 
bands (cm-1) 
Associated functional 
groups from IR bands  
AZT 3458.92 3500 - 3300 Medium N-H stretching bands 
2974.83 3200 - 2500 O-H stretching 
2813.97 
2081.50 2160-2120 Strong N=N=N stretching 
1669.58 1685-1666 Strong C=O stretching 
PLGA 50:50 2950.52 2960 - 2850 Chelated O-H stretching bridge 
1750.32 1800 – 1750 C=O stretching of the carbonyl 
group 
PLGA 85:15 2996.25 3000 - 2500 Chelated O-H stretching bridge 
1746.64 1790 - 1740 Strong C=O stretching of the 
carbonyl group 
AZT-PLGA 
50:50 physical 
mixture 
3461.12 3500 - 3300 Medium N-H stretching bands 
3023.15 3000 - 2500 Chelated O-H stretching bridge 
2814.57 3200 - 2500 O-H stretching 
2082.39 2160-2120 Strong N=N=N stretching 
1751.54 1770 - 1710 Strong C=O stretching 
1679.98 1685-1666 Strong C=O stretching 
AZT-PLGA 
85:15 physical 
mixture 
3460.60 3500 - 3300 Medium N-H stretching bands 
3023.04 3000 - 2500 Chelated O-H stretching bridge 
2082.15 2160-2120 Strong N=N=N stretching 
1750.91 1770 - 1710 Strong C=O stretching 
1677.09 1685-1666 Strong C=O stretching 
  
FT-IR spectra of pure PLGA 50:50 and PLGA 85:15 was the same as discussed in 
chapter 4 Figure 4.2 b & c. AZT on the other hand shared characteristic peaks similar 
to TDF (Figure 4.2a). Similarities such as N-H, and O-H groups at 3458.92 cm−1 and 
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2974.83 cm−1 stretching vibrations respectively, however AZT also presented with 
differences such as lack of the C=C (1752.31 cm−1) found in TDF and the presence of 
N3 group present at 2081.50 cm−1 in AZT but absent in TDF. These unique stretching 
areas were expected given the respective structures below. 
 
Figure 5.1: Structure of (a) AZT  and (b ) PLGA (n represents the number of lactic acid 
units while m represents the number of glycolic acid units) 
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Figure 5.2: FT-IR spectra of (a) AZT, (b) PLGA 50:50, (c) PLGA 85:15, (d) AZT-PLGA 
50:50 physical mixture, (e) AZT-PLGA 85:15 physical mixture 
When compared to the FT-IR spectrum of either AZT or the polymer alone, the 
physical mixture of AZT-PLGA 50:50 and AZT-PLGA 85:15 (Figure 5.2(d) and (e), 
respectively) showed  slight shifts in the bands of the resulting physical mixture as well 
as indicated some physiochemical interaction in the spectrum. AZT-PLGA 50:50 
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showed bands at 3461.12 cm−1, attributed to OH stretching; at 3023.15 cm−1 which 
were attributed to C-H stretching vibration; at 2814.57 cm−1 which was attributed to 
strong CH3 stretching vibration; at 2082.39 cm−1, attributed to N3 asymmetric stretching 
vibration; as well as at 1751.54 cm−1 and 1679.98 cm−1 which were attributed to C=O 
stretching vibrations. In Figure 5.2(e), AZT-PLGA 85:15 showed bands at 3460.60 
cm−1 attributed to OH stretching; at 3023.04 cm−1 attributed to C-H stretching vibration; 
at 2082.15 cm−1 attributed to N3 asymmetric stretching vibration; and at 1750.91 cm−1 
and 1677.09 cm−1 attributed to C=O stretching vibrations. AZT-PLGA 85:15 also 
presented with the disappearance of the O-H stretching vibration (2813.97 cm−1) which 
is present in the AZT-PLGA 50:50 physical mixture these may be because of the 
differences in PLGA ratios. No new peaks were observed, but the intensity of certain 
characteristic peaks such as 2950.52 cm−1 and 2996.25 cm−1 increased while those 
at 1750.32 cm−1 and 1746.64 cm−1 decreased in the physical mixture for PLGA 50:50 
and PLGA 85:15 respectively when compared to the parent compound further 
confirming an interaction taking place. 
Overall, both physical mixtures showed slight shifts and disappearance of 
characteristic peaks when compared to the parent compounds, thus indicating an 
interaction between AZT and PLGA.  
5.2.2 Hot stage microscopy  
The results presented below were obtained during sample analysis using hot stage 
microscopy (HSM). The compounds were analyzed individually as AZT, PLGA 50:50, 
PLGA 85:15, and in combination that is as a physical mixture of the polymer with AZT 
(mixed by grinding). The samples were heated up to a maximum temperature of 200°C 
at a temperature increase rate of 10°C per min.  
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Figure 5.3: HSM of (a)AZT, (b)PLGA 50:50, (c)PLGA 85:15, (d)AZT-PLGA 50:50 
physical mixture, (e)AZT-PLGA 85:15 physical mixture 
Figure 5.3(a) shows images taken during HSM analysis of AZT. The melting of AZT 
commenced at 120°C and continued up till 125°C. No bubbles were observed during 
this process, indicating that no moisture was contained in the sample. At 130°C, the 
sample had completely melted. The degradation of AZT, observed by discoloration of 
the sample, started at about 180°C. The results obtained from this analysis were in 
line with the certificate of analysis which indicated that the melting point of AZT is 
between 120°C and 127°C. Figure 5.3b & c are HSM images of PLGA 50:50 and 
PLGA 85:15, which have been discussed in chapter 4, section 4.2.2. 
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Figure 5.3d shows HSM images of the copolymer and AZT physical mixture (AZT-
PLGA 50:50). Melting commenced at about 30°C, with the appearance of bubbles 
observed at about 110°C. The appearance of bubbles was an indication of moisture 
being trapped under the slide covering the sample. Unlike the case with TDF-PLGA 
50:50 physical mixture (Figure 4.3 d), the bubbles did not disappear, however; as 
noticed with TDF-PLGA 50:50 physical mixture, sign of degradation such as browning 
of the sample was noticed at a temperature of about 160°C. 
Figure 5.3e shows images from HSM analysis of AZT and the polymer (AZT-PLGA 
85:15 physical mixture). As with AZT-PLGA 50:50 physical mixture, melting 
commenced at about 30°C, with the appearance of bubbles, noticed at about 120°C. 
This temperature is around the melting point of AZT, thus confirming the presence of 
AZT in the physical mixture. The appearance of the bubble was an indication of 
moisture being trapped under the slide covering the sample. The bubbles did not 
disappear on continued heating but rather increased in size. Degradation, such as 
browning of the sample appeared at about 160°C. Since the initial polymer did not 
show any sign of degradation under HSM analysis (Figure 5.3c) whereas AZT 
degraded (Figure 5.3a), such degradation in AZT-PLGA 85:15 physical mixture could 
further infer the presence of AZT in the sample. 
5.2.3 Thermogravimetric analysis (TGA)  
Changes in thermal stability, organic solvent evolution and the degradation form of 
AZT, PLGA 50:50, PLGA 85:15, and a combination of both polymers with AZT (mixed 
by grinding) was evaluated using TGA. Figure 5.4 shows the curves obtained when 
the samples were analyzed. There was release of volatile species, and  weight loss 
due to moisture was observed. 
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Figure 5.4: TGA curves of (a) AZT-PLGA 85:15 physical mixture, (b) PLGA 85:15, (c) 
AZT-PLGA 50:50 physical mixture, (d) AZT, (e) PLGA 50:50 
Both polymers (PLGA 50:50 and PLGA 85:15) showed two mass loss events 
associated with the degradation process [Figure 5.4 (b) and (e)]. The first mass losses 
for PLGA 50:50 and PLGA 85:15 were about 30% and 65%, respectively. The second 
mass loss peak showed values of about 68% and 35% for PLGA 50:50 and PLGA 
85:15, respectively. Unlike PLGA 85:15, PLGA 50:50 did not exhibit a 100% mass loss 
event; it had about 2% inert residue.  
The drug-polymer physical mixtures (AZT-PLGA 50:50 and AZT-PLGA 85:15) were 
also analyzed via TGA [Figure 5.4 (a) and (c)]. The physical mixture with PLGA 50:50 
showed two mass loss events while the physical mixture with PLGA 85:15 which 
showed a single mass loss event. The individual components (polymer and AZT) 
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showed two mass loss events. These differences in the TGA results between the 
individual components and the resulting physical mixture could be a result of 
differences in the polymer ratios and molecular weights (Appendix C, Table C1.8). The 
percentage weight loss for AZT-PLGA 50:50 and AZT-PLGA 85:15 were about 94% 
and 97%, respectively. The Tonset values however were at a lower temperature when 
compared to that of either polymer or AZT alone.  
5.2.4 Differential Scanning Calorimetry (DSC) 
Figure 5.5a presents the thermogram of AZT; the peak indicated that the melting point 
of AZT was about 124.80°C which was in accordance with the melting point of AZT in 
literature.[1] The thermograms for PLGA 50:50 and 85:15 Figure 4.5a are discussed in 
chapter 4 section 4.2.4. 
(a)
(b) 
Figure 5.5: DSC Thermograms of Zidovudine, AZT-PLGA 50:50 and AZT-PLGA 85:15 
physical mixtures 
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Figure 5.5b above presents thermograms of AZT when it was mixed and ground 
separately with PLGA 50:50 and PLGA 85:15. The thermograms indicated both 
physical mixtures had single peaks which indicated the melting point started from 
57.48°C to 58.51°C for physical mixtures of AZT-PLGA 50:50 and AZT-PLGA 85:15 
respectively. Comparing the physical mixture to PLGA alone (Figure 4.5), the plot 
indicated that the presence of AZT increased the stability of PLGA; however, a peak 
indicating the presence of AZT could not be seen. The lack of an AZT peak may 
perhaps be because too little of the AZT was used. 
5.3 Formulation and characterization of AZT loaded nanoparticles  
Figure 5.6 below shows diagrammatically each step in the formulation of AZT-loaded 
nanoparticles, formulation was done using the water-in-oil-in-water double emulsion 
solvent evaporation and diffusion method by Liu et al., 2010  with modifications to 
decrease nanoparticle size and increase encapsulation efficiency. 
 
Figure 5.6: Schematic presentation of AZT-loaded nanoparticle formulation process 
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5.3.1 Particle size and distribution (polydispersity index, PDI) 
The particle sizes of AZT-PLGA (50:50 and 85:15) loaded nanoparticles were 
measured, immediately after formulation and evaporation of the organic solvents from 
the sample, using dynamic light scattering (Malvern system). The mean particle sizes 
for AZT-PLGA 50:50 and AZT-PLGA 85:15 were found to be 110.6 ± 0.42 nm and 
112.0 ± 2.43 nm, respectively (Table 5.2). 
Table 5.2: Particle size of AZT-loaded nanoparticles. 
Formulated nanoparticles  Particle size (nm) 
Before wash After wash 
AZT-PLGA 50:50 110.6 ± 0.42 154.3 ± 3.1 
AZT-PLGA 85:15  112.0 ± 2.43 160.4 ± 1.7 
 
The postulated mechanisms to show how particles pass through the gastrointestinal 
and physiological barriers highlights endocytosis as one of the mechanisms, for 
particles < 500 nm. The particle sizes of the nanoparticles increased after they were 
washed three times with distilled water. The average size for AZT-PLGA 50:50 and 
AZT-PLGA 85:15 nanoparticles after washing was found to be 154.3 ± 3.1 nm and 
160.4 ± 1.7 nm respectively (Table 5.2). The increase in particle size could be a result 
of the particle aggregation after surfactants and emulsifiers had been removed by the 
washing process. Particles size of formulated nanoparticles plays an important role in 
drug pharmacokinetics. The smaller the particle sizes of the drug / formulation, the 
higher the rate of particle absorption from the intestine into the blood stream. [1,2] A high 
uptake of particles can be expected because of the relatively small sizes of the 
nanoparticles formulated.  
The polydispersity index (PDI) values for AZT-PLGA 50:50 and AZT-PLGA 85:15 after 
formulation were found to be an average of 0.165 ± 0.004 and 0.152 ± 0.015, 
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respectively. These values increased to 0.418 ± 0.004 and 0.376 ±0.17 for AZT-PLGA 
50:50 and AZT-PLGA 85:15, respectively, after the washing process (Table 5.3). 
 Table 5.3: Polydispersity index of AZT-loaded nanoparticles. 
Formulated nanoparticles  Polydispersity index 
Before wash After wash 
AZT-PLGA 50:50 0.165 ± 0.004 0.418 ± 0.004 
AZT-PLGA 85:15  0.152 ± 0.015 0.376 ± 0.17 
 
The PDI values are indicative of a largely homogenous distribution of the 
nanoparticles.[3] Values of PDI closer to one (1) indicate a heterogeneous distribution 
of nanoparticles while values closer to zero (0) indicate a homogenous distribution of 
nanoparticles[4] The increase in PDI value could be as a result of formulated pellets 
fusing together after removal (washing off) of the surfactants and emulsifiers, hence 
making the distribution more heterogeneous when compared to the characteristic prior 
to the washing process. 
5.3.2 Evaluation of surface morphology of the nanoparticle  
The morphology (shape and properties) of the nanoparticles was determined using a 
high-resolution scanning electron microscopy (HR-SEM). Figure 5.7 shows images of 
blank nanoparticles of PLGA 50:50 and PLGA 85:15, AZT-PLGA 85:15 and AZT-
PLGA 50:50 loaded nanoparticles. [Figure 5.7 (a) and (b)] are blank HR-SEM images 
of blank nanoparticles of PLGA 50:50 and PLGA 85:15, respectively; the images 
showed the particles were spherical in shape with smooth surfaces. 
Figure 5.7(c) shows HR-SEM images of AZT-PLGA 85:15 loaded nanoparticles. From 
the image, it was observed that the particles were spherical in shape with smooth 
surfaces, with an average particle size above 200 nm (which was greater than the 
maximum size observed with the zeta sizer (160 nm). The increase in size might be a 
result of aggregation and coalescence of the small nanoparticles. Such aggregating 
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and coalescing behavior may be a consequence of the freeze-drying process, which 
may cause the nanoparticles to irreversibly fuse, hence increasing the particle size. 
Freezing of the samples can also cause mechanical stress on the nanoparticles 
leading to a change in particle morphology. As earlier mentioned, (Section 4.3.2), 
aggregation of formulated nanoparticles may be minimized (Pirooznia et al., 2012). 
 
Figure 5.7: HR-SEM of formulated nanoparticles (a) Blank PLGA 50:50, (b) Blank 
PLGA 85:15, (c) AZT-PLGA 85:15 loaded, and (d) AZT-PLGA loaded nanoparticles 
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Figure 5.7d shows images of AZT-PLGA 50:50 loaded nanoparticles taken with HR-
SEM. Similar characteristics to those of AZT-PLGA 85:15 (Figure 5.7c) were 
observed; the nanoparticle surface was smooth and spherical, with signs of 
aggregation and coalescence.  
When Figure 5.7 (a) and (b) were compared to Figure 5.7c and Figure 5.7d, the latter  
appeared to be less smooth and more coagulated; this might be as a result of the 
presence of AZT in the formulation. 
5.3.3 Zeta potential  
The zeta potential after formulation of the AZT-PLGA 50:50 and AZT-PLGA 85:15 
loaded nanoparticles (Table 5.4) was determined using the Malvern system. The mean 
zeta potential for AZT-PLGA 50:50 and AZT-PLGA 85:15 were found to be -4.82 ± 
0.62 mV and -5.41 ± 0.02 mV, respectively. These values had decreased to -15.3 ± 
0.5 mV and -12.2 ± 0.6 mV, respectively, after washing of the samples, an indication 
that the stability of the nanoparticles had increased. The negative charge on the 
nanoparticles directly affects the cellular uptake of the nanoparticles by inducing a 
positive charge on the cell membrane, resulting in attraction between the two surfaces. 
This may result in higher bioavailability of AZT, as the drug-loaded nanoparticles may 
be better able to permeate the cell membrane and be transported to endosomes found 
within the cell.[6] 
Table 5.4: Zeta potential of AZT-loaded nanoparticles.  
Drug Polymer ratio  Zeta potential 
Before wash After wash 
AZT-PLGA 50: 50 -4.82 ± 0.62 mV -15.3 ± 0.5 mV 
AZT-PLGA 85: 15  -5.41 ± 0.02 mV -12.2 ± 0.6 mV 
 
 
 
http://etd.uwc.ac.za/
Chapter 5: Results and discussion of AZT PLGA nanoparticle 
119 
 
5.3.4 Percentage yield  
After freeze drying, the AZT-PLGA 50:50 and AZT-PLGA 85:15 loaded nanoparticles 
were recovered and weighed. The values obtained after weighing were 83.1 mg and 
67.02 mg, respectively (Table 5.5). The percentage yield, calculated as detailed in 
Equation 3.2,  
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑦𝑖𝑒𝑙𝑑(%) =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑃𝐿𝐺𝐴, 𝑑𝑟𝑢𝑔 𝑎𝑛𝑑 𝑒𝑥𝑐𝑖𝑝𝑖𝑒𝑛𝑡𝑠
 𝑢𝑠𝑒𝑑 𝑖𝑛 𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 
𝑥100 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑦𝑖𝑒𝑙𝑑(%) =
83.1 
105 𝑚𝑔
𝑥100 
                                                            = 79.14% for AZT-PLGA 50:50 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑦𝑖𝑒𝑙𝑑(%) =
67.02 
105 𝑚𝑔
𝑥100 
                                                            = 63.83% for AZT-PLGA 85:15 
The percentage yield was calculated to be 79.14% and 63.83%, respectively. The 
unbound polymer and drug could have been washed out and discarded during the 
washing process, resulting in the observed mass loss. 
Table 5.5: Mass of AZT-loaded nanoparticles recovered (mg) and percentage yield. 
Drug polymer 
combination 
Mass of AZT used 
in formulation 
(mg) 
Mass of 
polymer 
used 
(mg) 
Mass of 
nanoparticle 
recovered 
(mg) 
Percentage 
yield (%) 
AZT-PLGA 50:50 5 100 83.1 79.14 
AZT-PLGA 85:15 5 100 67.02 63.83 
 
5.3.5 Standard calibration plot for determination of AZT (HPLC-DAD and UV-
spectrometry method) 
The linearity of the methods was determined by analyzing the samples at an 
absorbance frequency of 266 nm, at which AZT had been proven to have its maximum 
absorbance.[7] A linear regression model was used to study the relationship between 
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absorbance of AZT and its concentration, and a graph of mean AZT absorbance 
versus AZT concentration was plotted (Figure 5.8). This model enabled the prediction 
of AZT concentration in the prepared nano-formulations by measuring its absorbance 
in the sample; data obtained is featured in appendix C (Table C1.6 and Table C1.7) 
 
Figure 5.8: Standard calibration graph of Zidovudine (λmax=266nm).  
Stock solutions and working standards were prepared in PBS at a pH of 1.2 and pH 
7.4. Samples were analyzed at 25ºC. Data values were recorded in triplicate and are 
presented as mean ± SD (n=3). 
Table 5.6 presents computed data derived from plotting the calibration curves for AZT. 
The R2 values at pH 1.2 and pH 7.4 depicted linearity and showed how close the data 
was to the fitted regression line. The relationship between concentration and 
absorbance can be expressed using Equation 5.1 with substitutions from Table 5.6 
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the amount of drug encapsulated within the nanoparticles was determined. Data 
obtained is featured in appendix C (Table C1.6 and Table C1.7).  
𝑦 = 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 + 𝑠𝑙𝑜𝑝𝑒(𝑥)   
Equation 5.1 
Where y = AZT peak area  
            x = the standard solution concentration in µg/ml 
Table 5.6: Linearity data and quantification limits of AZT at pH 7.4 and 1.2 (HPLC-
DAD and UV-spectrometry methods). 
Validation 
parameters  
HPLC-DAD  UV-spectrometry  
 pH 1.2 pH 7.4  pH 1.2 pH 7.4 
R2 0.9999 0.9979 0.9951 0.9986 
Slope ± SD 6181.304±27.59 8334.304±241.78 0.0381±0.0012 0.0654±0.00058 
Intercept ± SD 0.8246±1.99 6.1803±17.44 0.0164±0.0086 0.00921±0.0042 
Concentration 
range (µg/ml) 
0.02-0.12 0.02-0.12 200-1200 200-1200 
LOD (µg/ml) 0.001 0.007 0.75 0.40 
LOQ (µg/ml) 0.001 0.021 2.26 1.19 
  
Unlike what was obtained with the calibration plot for TDF, HPLC-DAD did not 
necessarily present better linearity values than analyses done with UV-spectrometry. 
The values obtained at pH 7.4 were also not necessarily better than those obtained at 
pH 1.2. It seems the HPLC-DAD method was more precise than the UV-spectrometry 
method at pH 1.2, while the UV-spectrometry method was more precise than the 
HPLC-DAD method at pH 7.4. However, the concentration ranges, as well as the LOD 
and LOQ values are lower for the HPLC-DAD method than for the UV-spectrometry 
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method (as was obtained with TDF analyses), attesting to the increased sensitivity of 
the HPLC-DAD compared to the UV-spectrometry method. 
Repeatability, precision and accuracy of the methods (HPLC-DAD and UV-
spectrometry methods) were assessed by analyzing replicates of AZT standard 
solution over a period of three days. Three different concentrations (0.02,0.06, 0.12 
and 2, 6 and 12 µg/ μl ) covering the standard calibration range of AZT were selected 
and analyzed to determine the inter-day and intra-day variability as shown in Table 5.7 
and Table 5.8. The intermediate precision and precision of the method at both pH 1.2 
and 7.4 were expressed as % RSD and found to be less than 2% for both HPLC-DAD 
and UV-spectrometry which suggested that the above methods were reproducible.  
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Table 5.7: Intra-day and inter-day assay precision and accuracy for Zidovudine at pH 
1.2 and 7.4 (HPLC-DAD method) 
 pH 1.2  pH 7.4 
AZT (µg/ μl) 0.02 0.06 0.12  0.02 0.06 0.12 
 Intra-day (n=3) 
 Day 1 
Mean  0.0203 0.0599 0.1207  0.0192 0.0591 0.1167 
SD 0.0002 0.0010 0.0012  0.0001 0.0008 0.0020 
Precision1 (%) 0.99 1.67 0.99  0.52 1.40 1.70 
Accuracy2 (%) 101.5 99.8 100.58  96 98.5 97.25 
Day 2 
Mean  0.0204 0.0600 0.1205  0.0193 0.0591 0.1167 
SD 0.0004 0.0010 0.0020  0.00012 0.0008 0.0005 
Precision1 (%) 1.96 1.67 1.66  0.62 1.35 0.43 
Accuracy2 (%) 102.00 100.00 100.4  96.5 98.5 97.3 
Day 3 
Mean  0.0201 0.0597 0.1207  0.0190 0.0588 0.1166 
SD 0.0001 0.0009 0.0018  0.0002 0.0003 0.0007 
Precision1 (%) 0.50 1.51 1.49  1.05 0.50 0.60 
Accuracy2 (%) 100.5 99.5 100.6  95 98 97.2 
Inter-day (n=9) 
Mean3 0.0203 0.0599 0.1206  0.0192 0.059 0.1167 
SD 0.00012 0.00012 0.000094  0.00012 0.00014 0.000047 
Precision1 (%) 0.59 0.20 0.08  0.63 0.24 0.04 
Accuracy2 (%) 101.5 99.83 100.5  96 98.33 97.25 
 
The results for accuracy (expressed as percentage of the mean determined 
concentration / nominal concentration) fell within the range, 95-102%. The acceptable 
mean recovery range in assays for quality control and drug registration is between 90 
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and 110%.[7] Thus, the accuracy and validity of the HPLC-DAD and UV-spectrometry 
method for AZT analyses was proven. 
Table 5.8: Intra-day and inter-day assay precision and accuracy for Zidovudine at pH 
1.2 and 7.4 (UV-spectrometry method). 
 pH 1.2  pH 7.4 
AZT (µg/ μl) 2 6 12  2 6 12 
 Intra-day (n=3) 
 Day 1 
Mean  0.0920 0.2547 0.4644  0.0820 0.2303 0.4630 
SD 0.0007 0.0001 0.0007  0.0001 0.0001 0.0002 
Precision1 (%) 0.76 0.04 0.15  0.14 0.04 0.05 
Accuracy2 (%) 99.12 104.1 97.9  102.8 104.1 106.8 
 Day 2 
Mean  0.0923 0.2546 0.4656  0.0779 0.2185 0.44697 
SD 0.0018 0.0002 0.0002  0.0002 0.0002 0.0003 
Precision1 (%) 1.95 0.08 0.04  0.26 0.10 0.07 
Accuracy2 (%) 99.52 104.1 98.16  97.0 98.5 103.1 
 Day 3 
Mean  0.0924 0.2543 0.4637  0.0804 0.2193 0.4391 
SD 0.0015 0.0003 0.0029  0.000006 0.0001 0.00064 
Precision1 (%) 1.62 0.12 0.63  0.07 0.05 0.15 
Accuracy2 (%) 99.65 104.0 97.75  100.6 99.0 103.1 
 Inter-day (n=9) 
Mean3 0.0922 0.2545 0.4646  0.080121 0.22271 0.449701 
SD 0.0002 0.0002 0.0010  0.002083 0.006584 0.012198 
Precision1 (%) 0.22 0.08 0.22  2.60 2.96 2.71 
Accuracy2 (%) 99.39 104.06 97.94  100.2 100.5 103.7 
The values in Table 5.7 and Table 5.8 was calculated as follows;  
❖ 1Expressed as % RSD = (SD/mean) × 100. 
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❖ 2Calculated as (mean determined concentration/nominal concentration) × 100. 
❖ 3n = 3 days with three replicates per day 
5.3.6 Encapsulation efficiency 
The encapsulation efficiency was determined using Equation 3.6,  
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦(%)   
=   
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑡ℎ𝑒 𝑦𝑖𝑒𝑙𝑑 
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑 𝑑𝑢𝑟𝑖𝑛𝑔 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 
𝑥100 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦(%)   =   
3.69
5
𝑥100 
                                                                               = 73.82% for AZT-PLGA 50:50 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦(%)   =   
2.38
5
𝑥100 
                                                                             = 47.6% for AZT-PLGA 85:15 
Table 5.9 below presents the encapsulation efficiency and the total amount of drug in 
the yield. This was determined by dissolving 5 mg of the AZT-loaded nanoparticles in 
0.5 ml of ethyl acetate (in a 5 ml Eppendorf tube) with vortexing. The ethyl acetate was 
evaporated, and 3 ml of phosphate buffer solution (PBS) was added to the Eppendorf 
tube. The tube was vortexed, and the contents centrifuged at a speed of 10000 rpm 
for 15 minutes. Thereafter, the supernatant was collected, and the absorbance 
measured using the UV-spectrometer and HPLC-DAD system. The concentration of 
the drug in that sample was determined by extrapolating the absorbance value from 
the calibration plot of AZT in Figure 5.8. 
Table 5.9: Total amount of AZT in recovered nanoparticles and encapsulation 
efficiency 
Drug polymer combination  Amount of drug in 
nano-formulation (mg)  
Encapsulation 
efficiency (%) 
AZT-PLGA 50:50 3.69 73.82 
AZT-PLGA 85:15 2.38 47.6 
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the above results indicated that formulation with PLGA 50:50 showed about 26.22% 
increase in encapsulation efficiency of AZT when compared to formulation with PLGA 
85:15. Possible reasons for this could be the differences in the molecular weights and 
polymer ratios of PLGA 50:50 and PLGA 85:15. The encapsulation efficiency of AZT-
PLGA 85:15 suggested that less than half the initial amount of AZT used during the 
formulation process was recovered after formulation. The amount of AZT lost might 
be because of un-encapsulated drug discarded during the washing process. 
5.3.7 Drug entrapment efficiency 
The theoretical, actual loading and drug entrapment efficiency were calculated using 
the following equations;  
Equation 3.3,  
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (𝑇𝐷𝐿)(%) =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑 
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 𝑎𝑛𝑑 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑 
𝑥 100 
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (𝑇𝐷𝐿)(%) =
5
105 
𝑥 100 
                                    = 4.76% for both AZT-PLGA 50:50 and 85:15 
Equation 3.4  
𝐴𝑐𝑡𝑢𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (%) =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
𝑥100 
𝐴𝑐𝑡𝑢𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (%) =
3.69
83.1
𝑥100 
= 4.44% for AZT for PLGA 50:50 
𝐴𝑐𝑡𝑢𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (%) =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
𝑥100 
𝐴𝑐𝑡𝑢𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (%) =
2.38
67.02
𝑥100 
                                                                  = 3.57% for AZT-PLGA 85:15  
and Equation 3.5,  
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𝐷𝑟𝑢𝑔 𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦(%) =
𝑎𝑐𝑡𝑢𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 
𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 
𝑥100 
𝐷𝑟𝑢𝑔 𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦(%) =
4.44 
4.76 
𝑥100 
                                                                                    = 93.23% for AZT-PLGA 50:50 
𝐷𝑟𝑢𝑔 𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦(%) =
3.57 
4.76 
𝑥100 
                                                                              = 75% for AZT-PLGA 85:15   
Table 5.10 below presents data derived from the above calculations. The formulation 
with PLGA 50:50 showed higher encapsulation of the drug compared to the 
formulation with PLGA 85:15. The reasons for the difference in entrapment efficiency 
are yet unknown, our hypothesis (similar to that with the TDF formulations) is that this 
might be as a result of differences in the polymer ratios. The significance of this 
difference was however not calculated.  
Table 5.10: Actual and theoretical drug loading values, and drug entrapment 
efficiency of TDF-PLGA formulations. 
Drug polymer 
combination 
Theoretical 
drug loading 
(% w/w) 
Actual drug 
loading (% 
w/w) 
Drug entrapment 
efficiency (% w/w) 
AZT-PLGA 50:50 4.76 4.44 93.23 
AZT-PLGA 85:15 4.76 3.57 75 
 
5.3.8 Fourier Transform Infrared Spectroscopy (FT-IR) 
Figure 5.9 (c) and (d) present data from the FT-IR analysis of AZT-PLGA 50:50 and 
AZT-PLGA 85:15 loaded nanoparticles, respectively. The different intensity peaks 
showed that AZT was encapsulated within the polymer because, when compared to 
the FT-IR data obtained prior to formulation (Figure 5.9a and b), the characteristic 
intensity bands mostly corresponded to the polymer. The loaded AZT-PLGA 50:50 and 
AZT-PLGA 85:15 nanoparticles (Figure 5.9c & d) produced significantly less 
pronounced spectra. In the FT-IR spectra of the nano-formulation several peaks once 
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again shifted (compared to the  parent compound), disappeared and even new peaks 
appeared (comparatively to the physical mixtures). What this suggests is a clear 
indication of a more pronounced interaction between AZT and the polymers as well as 
that the polymer is indeed loaded with AZT. 
Figure 5.9d showed the appearance of an extra intensity peak at 2995.93 cm-1. This 
peak was not present in Figure 5.9c and may be because of differences in the 
polymers used. The loaded nanoparticles also indicated the disappearance of certain 
peaks such as at 3461.12 cm-1 and 3460.60 cm-1 (N-H stretching vibration), 2814.57 
cm-1 (O-H stretching) as well as 1751.54 cm-1 and 1750.91 cm-1 (C=O stretching) for 
AZT-PLGA 50:50 and AZT-PLGA 85:15 respectively. Figure 5.10 indicates the 
possible functional groups that may interact between AZT and PLGA based on the 
FTIR analysis obtained below. 
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Figure 5.9: FT-IR spectra of (a) AZT-PLGA 50:50 physical mixture, (b) AZT-PLGA 
85:15 physical mixture, (c) AZT-PLGA 50:50 loaded, and (d) AZT-PLGA 85:15 loaded 
nanoparticles 
 
Figure 5.10: Schematic representation of possible functional group interactions 
between AZT and PLGA  
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5.3.9 Hot stage microscopy  
Following collection of the freeze-dried AZT-loaded nanoparticles, the samples were 
analyzed using HSM. Figure 5.11a & b (AZT-PLGA 50:50 and AZT-PLGA 85:15 
physical mixtures) are as discussed in section 5.2.2 (Figure 5.3 d and e), respectively.  
Figure 5.11c shows images from the HSM analysis of AZT-PLGA 50:50 loaded 
nanoparticles. Melting of the sample with increase in temperature was noticeable 
around 45°C; however, sample melting was challenging to visualize. At 110°C, clear 
change such as melting of the sample was observed. There was no appearance of 
bubbles or visible degradation of the sample; this may be explained by the inference 
that the polymer completely encapsulated AZT and therefore protected it from 
degradation. It could also be because the amount of AZT in the formulation was too 
small for the degradation process to be visualized. At temperatures above 130°C, the 
sample appeared oily and viscous with no further changes observed with increase in 
temperature.  
 
Figure 5.11: HSM images of (a) AZT-PLGA 50:50 physical mixture, (b) AZT-PLGA 
85:15 physical mixture, (c) AZT-PLGA 50:50 loaded and (d) AZT-PLGA 85:15 loaded  
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Figure 5.11d above presents images from the HSM analysis of AZT-PLGA 85:15 
loaded nanoparticles. Melting of the sample with increase in temperature was a bit 
difficult to visualize at temperature changes between 30°C and 60°C; however, 
noticeable change such as melting of the sample was observed at temperatures above 
110°C. There was no appearance of bubbles, and no visible degradation of the sample 
was observed. This could possibly be explained by the fact that the polymer 
completely encapsulated AZT and therefore protected it from degradation. It may also 
be that the amount of AZT in the formulation was too small for the degradation process 
to be visualized. Unlike the case with AZT-PLGA 50:50 nano-formulation, the sample 
appeared to dry up when the temperature increased above 130°C. 
5.3.10 Thermogravimetric analysis (TGA) 
In Figure 5.12, data from the TGA of AZT-PLGA 50:50 and AZT-PLGA 85:15 loaded 
nanoparticles are presented. The AZT-PLGA 50:50 loaded nanoparticles exhibited a 
single mass loss event unlike AZT-PLGA 85:15 loaded nanoparticles which exhibited 
two mass loss events. This can be attributed to differences in polymer ratios and their 
molecular weights. During pre-formulation analysis however, the reverse was the 
case; the physical mixture of AZT-PLGA 50:50 exhibited two mass loss events while 
AZT-PLGA 85:15 exhibited a single mass loss event.  
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Figure 5.12: TGA curve of (a) AZT-PLGA 50:50 loaded and (b) AZT-PLGA 85:15 
loaded nanoparticles. 
These differences could perhaps be a result of insufficient trituration of the physical 
mixture and its components. It may also be due to a change in thermal stability of the 
products. These are only hypothetical currently; hence, may require further 
investigation.  
Table C1.10 appendix C presents data from the thermal analyses of AZT formulated 
nanoparticles. 
5.3.11 Differential Scanning Calorimetry (DSC) 
Figure 5.13 shows thermograms of AZT-PLGA 50:50 and AZT-PLGA 85:15 loaded 
nanoparticles. As was the case with TDF, no identifiable peaks of AZT could be seen 
in the thermograms. The reason for this could be that no crystalline AZT was found in 
the nanoparticles. It may also indicate that the amount of AZT present in the sample 
was too small to show any peaks, or that AZT is molecularly dispersed in the polymer 
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matrix. The loaded nanoparticles showed peaks that were present when AZT physical 
mixtures were analyzed (Figure 5.5b), with melting points of 55.25°C and 56.09°C for 
AZT-PLGA 85:15 and AZT-PLGA 50:50 respectively. It is however not known if these 
differences in temperature are significant. 
 
Figure 5.13: DSC thermograms of AZT-PLGA 50:50 and AZT-PLGA 85:15 loaded 
nanoparticles 
 
5.3.12 Determination of AZT release from AZT-PLGA loaded nanoparticles  
Figure 5.14 shows the cumulative percentage of AZT released from AZT-PLGA loaded 
nanoparticles at a pH 1.2 and pH 7.4 versus time. Samples were analyzed using two 
analytical methods, HPLC-DAD and UV-spectrometry. The release profiles from both 
analytical methods showed a biphasic release model with an initial burst of AZT 
followed by sustained release. This is typical of core-shell type nanoparticles.[8] The 
release profile also confirmed the presence of surface drug present on the 
nanoparticles, with the bulk of the AZT encapsulated within the nanoparticles. With 
such release kinetics, some level of extended release may possibly be obtained from 
the AZT-PLGA formulations. If this is the case, there may be no need for twice daily 
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dosing of AZT, thus making a formulation with once daily dosing, which can improve 
patient compliance and adherence to therapy. 
 
 
Figure 5.14: In-vitro release of AZT-PLGA 50:50 and AZT-PLGA 85:15 loaded 
nanoparticles  
The release studies were done at pH 1.2 (Figure 5.14 a & c) and pH 7.4 (Figure 5.14 
b & d) at 37˚C over a period of 48h, using the UV-spectrometry (Figure 5.14 a & b) 
and HPLC-DAD (Figure 5.14 c & d) analytical methods. Data was collected in 
triplicates and presented as mean ± SD (n=3). 
Table 5.11 indicates an approximation of the total percentage of AZT released within 
12 hours. Drug release from the same sample was quantified using two analytical 
equipment’s. Some differences were observed when the release curves from one 
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method were compared to the other method. Could this be a result of human error, or 
some other reason not yet fully understood? 
Table 5.11: Percentage of AZT released (12 hours analysis) 
AZT HPLC-DAD UV-spectrometry 
 pH 7.4 pH 1.2 pH 7.4 pH 1.2 
PLGA 50:50 28.7 % 58% 27% 61% 
PLGA 85:15 46.1% 68% 23% 39% 
 
After the initial burst, more of AZT was released from the nano-formulations over a 
period of time before a constant release was attained. The release profiles of both 
formulations indicated that more of AZT was released from the AZT-PLGA 85:15 
formulation when compared to the AZT-PLGA 50:50 formulation at pH 1.2 and pH 7.4 
when analyzed using the HPLC-DAD method; however, the reverse was the case 
when the sample was analyzed using UV-spectrometry. This difference may be due 
to differences in the different polymers with respect to molecular weight, ratio and 
composition. 
5.3.13 Mathematical modeling of drug release data 
The release mechanism of AZT from AZT-PLGA formulated nanoparticles was 
evaluated by fitting the release data to four mathematical models, namely; Gompertz 
model, Korsmeyer-Peppas model, Peppas-Sahlin model, and Weibull model. 
DDsolver, a peer-reviewed modelling program [9], was used for this analysis. The 
release data was fitted to each of the four mathematical models listed above; these 
models are the ones commonly used in literature.[10]  
The best fit model was selected by using the adjusted coefficient of determination (R² 
adj) and a model with the highest R² adj was deemed to be the best fitting model. R² 
adj allows for better comparison of the models when compared to the coefficient of 
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determination (R2).[11]  The release data of AZT obtained at both pH 1.2 and 7.4 was 
fitted to the four models mentioned above and it was determined that a majority of the 
formulations (3 out of 4) were best fit by the Weibull model. The exception was AZT-
PLGA 50:50 at pH 7.4 whose best fit model (according to the R2 adj value) was the 
Peppas-Sahlin model (Table 5.12). 
Table 5.12 below presents parameter values and R2adj values obtained from fitting 
drug release experimental data to the four mathematical models. The asterisked 
values correspond to the highest value of R2adj obtained when the four models were 
compared, for each sample. 
Parameters explaining the Weibull model are as discussed in chapter 4 section 4.3.13, 
The following samples were best fitted by Weibull model AZT-PLGA 85:15 at pH 7.4, 
AZT-PLGA 50:50 and AZT-PLGA 85:15 at pH 1.2, All three sample models displayed 
a β value less than 0.75, which implied that the release mechanism was by Fickian 
diffusion. 
Parameters in Peppas-Sahlin can be described as follows K1 is the constant that is 
related to Fickian kinetics (Fickian diffusion), K2 is the constant that is related to case-
II relaxation kinetics (matrix relaxation/erosion) and m is the diffusional exponent 
(ranges between 0 and 1).  
As mentioned earlier, AZT-PLGA 50:50 at pH 7.4 did not fit with the other release data 
for Weibull model; its model of best fit was the Peppas-Sahlin model (Table 5.12). The 
release parameters for AZT-PLGA 50:50 under the Peppas-Sahlin model showed that 
the k2 values were all negative. This indicates that k1 was the only mechanism of 
release, which inferred that AZT release from the formulation was by Fickian diffusion. 
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Table 5.12: Parameter values and R2adj values obtained from fitting drug release 
experimental data to four mathematical models 
pH   1.2 7.4   
 Parameters  AZT-
PLGA50:50 
AZT-
PLGA85:15 
AZT-
PLGA50:50 
AZT-
PLGA85:15 
 
Weibull_1  Β 0.15 0.05 0.07 0.07  
Α 1.32 1.22 3.67 3.67  
Ti 0.49 0.5 0.47 0.47  
R2adj 0.982* 0.993* 0.977 0.981*  
Gompertz_1 Α 0.84 0.77 1.50 1.13  
Β 0.70 0.30 0.14 0.32  
R2adj 0.957 0.937 0.969 0.930  
Peppas-
Sahlin_1 
K1 51.42 59.9 28.19 38.33  
K2 -9.03 -14.88 -6.75 -7.54  
M 0.33 0.24 0.24 0.30  
R2adj 0.971 0.968 0.998* 0.978  
Korsmeyer-
Peppas 
with Tlag 
N 0.08 0.03 0.06 0.07  
K 53.9 53.0 23.9 38.0  
R2adj 0.976 0.992 0.976 0.980  
 
5.3.14 Stability of AZT-PLGA loaded nanoparticles  
The formulated nanoparticles were stored at temperatures between 2 and 8°C. They 
were subsequently evaluated for stability by measuring parameters such as the 
particle size, zeta potential and PDI at the time of preparation and at different time 
intervals over a duration of 90 days. 
Particle size  
The average nanoparticle size after formulation was determined to be 122.4 ±1.48 nm 
and 110.4 ± 0.02 which increased to 155.3 ± 0.8 nm and 182.7 ± 3.7 nm after washing. 
These values further increased to 1941.3 ±32.21 nm and 1600 ± 74.8 nm after freeze 
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drying of the nanoparticles for AZT-PLGA 50:50 AZT-PLGA 85:15, respectively. 
During storage, the nanoparticles showed a steady pattern of increasing nanoparticle 
size with time (Figure 5.15). This was indicative of an increase in coalescence of the 
nanoparticles, and as such a decrease in stability with time. 
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Figure 5.15: Changes in nanoparticle size of TDF-PLGA 50:50 and 85:15 freeze dried 
loaded nanoparticles 
Upon comparison of the particle sizes, AZT-PLGA 85:15 showed a steady increase in 
particle over time, This was similar to the observation made with TDF-PLGA 85:15 
(Figure 4.15) As noted with TDF-PLGA 50:50, the particle sizes of AZT-PLGA 50:50 
also increased with time, albeit at a seemingly slower rate than was observed with 
AZT-PLGA 85:15. These differences in the rate of particle size increase may be due 
to differences in the copolymer ratios and their molecular weights. 
The postulated mechanisms to show how particles pass through the gastrointestinal 
and physiological barriers highlights endocytosis as one of the mechanisms, for 
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particles < 500 nm. It can therefore be seen that the nanoparticle sizes immediately 
after formulation and after washing favors uptake via endocytosis. Following the 
freeze-drying and 90-days storage processes however, the increase in particle size as 
mentioned above was such that endocytosis may not be favorable as an uptake 
mechanism. There may however be some success with uptake via lymphatic passage, 
with absorption by cells in Peyer’s patches, especially for particles less than 5 µm. It 
can be seen that the nanoparticle size increased after the washing process, possibly 
due to agglomeration of these particles. As with the TDF formulations a proposal may 
be made for more assessments of to limit such agglomeration after the washing 
process, perhaps by making use of suitable surface-active agents. Such an 
intervention may slow / prevent agglomeration, ensuring that particle sizes remain 
close to the values obtained immediately after formulation. This will enhance 
penetration through physiological barriers and hence improve bioavailability.  
Zeta potential  
The average zeta potential after formulation was determined to be -9.94 ± 0.02 mV 
and -5.11 ± 2.1 mV for AZT-PLGA 50:50 and AZT-PLGA 85:15, respectively. These 
values further decreased after washing, indicating an increase in stability. During 
storage, the zeta potential showed a steady increase in value, which is an indication 
of a decrease in stability of the nano-formulation with increase in time; however, on 
day 30, the sample showed some discrepancy indicating an increase in stability. The 
zeta potential further decreased from day 60 through day 90 (Figure 5.16). 
The same trend was also noticed with the TDF formulations (section 4.3.14 and Figure 
4.16). Was there perhaps some condition that improved stability on day 30, only to 
compromise such stability afterwards? This may be the subject of further studies. 
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Figure 5.16: Changes in zeta potential of AZT-PLGA 50:50 and AZT-PLGA 85:15 
freeze dried loaded nanoparticles. 
Polydispersity index  
The PDI values of the formulated nanoparticles were also assessed immediately after 
formulation. The values were 0.193 ±1.2 and 0.159 ± 0.02 for AZT-PLGA 50:50 and 
AZT-PLGA 85:15 respectively. The PDI values after day 10 of storage showed signs 
of increased coalescence of the nanoparticles. A steady increase in the PDI values 
was expected over time, however, on days 20, 30, 60 and 90, a drop was noticed in 
the PDI values, indicating less coalescence. It is our hypothesis that the molecular 
weight and copolymer ratios may be a factor responsible for these differences. (Figure 
5.17). 
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Figure 5.17: Changes in PDI of AZT-PLGA 85:15 and AZT-PLGA 50:50 freeze dried 
loaded. 
The overall changes in the nanoparticle size, zeta potential and PDI over the duration 
of storage were indicative of a decrease in stability of the formulated nanoparticles 
over time.  
Comparing the results obtained from characterizing AZT-loaded nanoparticles with the 
work done by Pet r Christoper et al., 2014 it could be determined that the author 
formulated nanoparticles  which were less than 100 nm  in size as opposed to the 
values obtained in the preset study (particle sizes greater than 100 nm). The present 
formulation with AZT-PLGA 50:50 yielded a higher encapsulation efficiency (73.8%) 
when compared to the value (59.50%) obtained by Peter Christoper et al., 2014. Peter 
Christoper et al., 2014 also modeled the drug release profile and found it to fit the 
Higuchi model while for this study, the release profile fit best to the Weibull and 
Peppas-Sahlin models.  
Chapter 6 will follow with an overall conclusion of the study.  
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CHAPTER 6: CONCLUSION AND RECOMMENDATIONS 
Co-formulation of TDF and AZT with PLGA to produce TDF-PLGA and AZT-PLGA 
nanoparticles, respectively, was the overall aim of this study. Producing these 
nanoparticles would in turn improve absorption and reduce the dose of drug required 
to attain therapeutic concentrations, thereby improving bioavailability and reducing the 
adverse effects associated with the use of these APIs when administered orally. 
The overall objectives of the study were:  
❖ to characterize AZT, TDF and PLGA 
❖ to formulate non-covalent complexes of TDF and AZT with PLGA of different 
ratios (50:50 and 85:15); 
❖ to characterize and compare physicochemical properties of the formulated 
complexes using various analytical techniques;  
❖ to compare the pharmaceutical properties (i.e. particle size, stability and in-vitro 
release studies) of the formulated complexes as a means of addressing some 
of the limitations associated with the optimal delivery of TDF and AZT (e.g. low 
permeability, low bioavailability).  
The above objectives were achieved by formulating nanoparticles using a modified 
water in oil in water (w/o/w) double emulsion solvent evaporation and diffusion method 
which had been proven to be efficient in encapsulating hydrophilic drugs.[1] Part of the 
hypothesis was successfully achieved when AZT and TDF were successfully co-
formulated to produce AZT-loaded and TDF-loaded nanoparticles. 
Nanoparticles of relatively small sizes in the range of 103 to 160 nm were successfully 
formulated, with PDI and zeta potential values indicating good homogeneity (PDI of 
less than 0.4) and good stability of the formulated nanoparticles (zeta potential of up 
to -19 mV). These smaller particle sizes play an important role as they are likely to be  
absorbed from the small intestine in greater proportions than the larger nanoparticles.  
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Analysis on FTIR provided spectra which were indicative of TDF and AZT 
encapsulation within the formulated nanoparticles. This was characterized by shifts, 
disappearance, appearance, increase or decrease in the intensity of the characteristic 
peaks when both formulations where compared to the parent compounds and physical 
mixtures of TDF and AZT with the polymers. 
A significant visual difference was noticed when the nanoparticles where analyzed 
using SEM; the blank nanoparticles showed surfaces that were smother than the 
loaded nanoparticles. This difference was explained by the APIs presence in the 
nanoparticles. This study recommends both TEM and SEM analysis be performed on 
the APIs and physical mixtures with PLGA based on the absence of such data in 
previous studies and comparative analysis with loaded samples. 
TEM on the loaded nanoparticles based on magnification of microscopic image may 
provide physical image of the loaded PLGA with the API visible in the micelle. Further 
structural elucidation could  be determined using X-ray diffraction. 
Both formulated nanoparticles of TDF and AZT showed high percentage yields greater 
than 50%, with high entrapment values (67-85% for TDF and 75-93% for AZT) and 
low encapsulation efficiency of less than 50%. An exception was the AZT-PLGA 50:50 
formulation which presented with an encapsulation efficiency as high as 73.82%, a 
value which is 24.02% more than the second highest encapsulation efficiency obtained 
from the four formulations (TDF-PLGA 85:15). It is uncertain at this stage if this 
difference is significant. The limitations to this value are highlighted in chapters 4 and 
5.  
The developed method of formulation was sound and the API to polymer ratio should 
be reviewed for a possible increase in concentration of API to be included in 
subsequent studies. 
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The in vitro release profile of both formulations (TDF and AZT) suggested that the 
release profile was biphasic; firstly, there was an initial burst of the API which 
confirmed the presence of surface API in the formulated nanoparticles, followed by a 
sustained release. Overall, the release profile revealed that more of the API was 
released at pH 1.2 when compared to the release profile of the same formulation at 
pH 7.4 (Table 4.11 and Table 5.11). This was confirmed by both HPLC-DAD and UV-
spectrometry analyses and it agreed with studies by Pamula and Menaszek et la, 2007 
who stipulated that the surrounding medium influences the degradation process. 
The total percentage of API released proposed that not all of the encapsulated drug 
was released within the 48-hour period. Hence, 48 hours is not sufficient time to 
achieve complete polymer swelling and degradation to facilitate drug diffusion from 
the nanoparticles.  
Chapters 4 and 5 release data fit well to four Mathematical models, i.e. with the 
Peppas-Sahlin (only for AZT-PLGA 50:50 at pH 7.4) and the Weibull models (for all 
other  formulations) as the best fit models. This also confirmed that the main 
mechanism of drug release from the formulated nanoparticles was by Fickian diffusion 
of the drug molecule from the nanoparticle core. Dissolution is a kinetic process and 
is quantified by the drug’s rate of solubility in solution. Solubility quantifies the dynamic 
equilibrium state achieved when the rate of dissolution equals the rate of precipitation. 
Since release studies were not performed for the free drugs, the nanoparticle release 
profile was compared to the free drug release profile performed by Shailender et al., 
2017 and Uronnachi et al., 2014 for TDF and AZT, respectively and to the calibration 
curve used to analyse the HPLC data. Shailender et al., 2017 and Uronnachi et al., 
2014 established that the free drugs were completely released in less than four hours 
of testing. This confirmed that sustained release was achieved which can led to an 
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improvement in bioavailability and reduction of adverse effects associated with the use 
of these APIs thereby proving the hypothesis. In-vivo studies are however 
recommended to further test this hypothesis.  
All drug formulations have to be tested for stability. The shelf-life of the product is 
dependent on such studies. Gradual changes in the stability of the nanoparticles was 
noticed after just 10 days of storage (2°C to 8°C). The sample showed a decrease in 
stability; however, these changes were not drastic, therefore the samples were not 
stable for a duration of 90 days at temperatures between 2°C to 8°C. It is our 
recommendation that the stability of samples be evaluated at room temperature at 
well.  
According to literature, there are several factors and different mechanisms of polymer 
degradation to release encapsulated drugs.[2] (mentioned in chapter 2). Firstly, PLGA 
containing both D- and L- forms of PLA was purchased, a combination of both forms 
prevents concerns of prolong or fast degradation. In 1999 Tracy et la, stated that PLGA 
with acid terminated ends showed a 2-3-fold increase in degradation rate when 
compared to ester terminated PLGA. Thus, this influenced the purchase of ester 
terminated PLGA for this study which has been proven to degrade slower.[3] . 
Finally, the results obtained showed that non-covalent nanoparticles were successfully 
formulated. Evaluation of the formulated nanoparticles revealed that future studies are 
needed to improve encapsulation efficiency, i.e., further work is needed to minimized 
wastage to improve the overall yield and stability, which can translate to a high 
percentage yield. Further work on in vivo analysis could also be performed to assess 
the ability of the nano-formulations to attenuate the limitations of the APIs.  
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Appendices 
Appendix A: Method development for formulation of TDF and AZT loaded 
nanoparticles 
Appendix A presents the different methods assessed to achieve the desired method 
for formulation of TDF and AZT loaded nanoparticles utilized in this study. The 
following general method was applied to prepare the nanoparticles, NP (methods A-
F). 
The general method  
1. 100 mg of polymer was weighed and dissolved in 10 ml of ethyl acetate: 
acetone (4:1 ratio) containing 5% v/v tween 80 in a beaker. 
2. 5 mg of API was dissolved in 1 ml of distilled water in a separate beaker. 
3. (2) was sonicated in (1) at a speed of 5000 rpm for 30 seconds, in an ice bath. 
The mixture was then homogenized at 87 kHz for 2 minutes in the ice bath to 
form the primary emulsion (w/o). 
4. (3) was added dropwise into 40 ml of water and sonicated at a speed of 12000 
rpm for a further 2 minutes to form the secondary emulsion (w/o/w). Thereafter, 
the mixture was homogenized at 87 kHz for 3 minutes. 
5. The w/o/w double emulsion was then poured gradually into a beaker containing 
0.05% w/v gelatin dissolved in water while stirring with a magnetic stirrer at 400 
rpm.  
6. The solution (5) was then continuously stirred at 400 rpm at a temperature of 
30 degrees centigrade for 6 hrs. This served to evaporate the organic solvents 
i.e. ethyl acetate and acetone completely, leaving a white cloudy emulsion (the 
formed nanoparticles). 
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7. The nanoparticles where spun in a centrifuge at a speed of 16000 rpm for 30 
min to collect the pellets (loaded nanoparticles). 
8. The pellets where washed three times with distilled water. 
ORGANIC SOLVENT  
The first organic solvents (dichloromethane and acetone) used were selected 
because of its ready availability in the laboratory. However, neither of the two 
solvents could dissolve the polymer, and when used in combination, the polymer 
precipitated after homogenization (Appendix, Figure A1.1). The goal at this stage 
was to select an organic solvent that could solubilize the polymer to continue the 
study. 
A. Organic solvent: Dichloromethane / Acetone  
Dichloromethane and acetone were used alone and in combination (ratio 4:1), (Figure 
A1.1a). The organic solvents ( was able to dissolve the polymer completely; however, 
the polymer precipitated upon addition of the aqueous phase during homogenization/ 
sonication (Figure A1.1 b). Thus, the sample and the method with selected solvent 
mixture used was rejected.  
 (a) (b) 
Figure A1.1: Result of polymer dissolution in the organic solvents (dichloromethane 
and acetone) 
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B. Organic solvent: chloroform  
Chloroform was used alone as the organic solvent at this stage of experimentation, 
because the goal was to select a suitable organic solvent with a low boiling point thus 
capable of evaporating quickly. NPs were successfully produced but were not 
subjected to washing because the particle sizes obtained were larger than the 
expected value of less than 150 nm (Table A1.1). Chloroform had proven to solve the 
issue (precipitation of the polymer after homogenization) encountered with 
dichloromethane and acetone; however, it still presented its own shortcomings as 
particle size obtained was larger than required. 
Table A1.1: Particle size, polydispersity index and zeta potential of formulated AZT 
or TDF nanoparticle obtained with chloroform as the organic solvent. 
Solvent  Particle size (nm)  Polydispersity index  Zeta potential  
Before 
wash  
After 
wash  
Before 
wash  
After wash  Before 
wash  
After 
wash 
Chloroform  354.1 - 0.198 - -0.361 - 
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C. Organic solvent: Ethyl acetate  
Ethyl acetate was also tested as an organic solvent. The results are presented in Table 
A1. 2.  
Table A1. 2: Particle size, polydispersity index and zeta potential of formulated 
nanoparticles obtained with ethyl acetate and changes in gelatin concentration. 
Solvent  
Ethyl acetate 
Gelatin 
(%) w/v 
Particle size 
(nm)  
Polydispersity 
index  
Zeta potential  
Before 
wash  
After 
wash  
Before 
wash  
After 
wash  
Before 
wash  
After 
wash 
Sample 1 (TDF)  0.5 1859 - 1 - - - 
Sample 2 (TDF) 0.5 
sonicated  
185 - 1 - 4  
Sample 3 (TDF) 0.2 392.4 - 0.371 - 3.01 - 
Sample 4 (TDF)  0.1 1603 - 0.274 - - - 
Sample 5 (TDF)  0.05  312  - 1 - 2.91  
Sample 6 (TDF)  0.05 
sonicated  
237.1 - 1 - 3.94 - 
Sample 7 (AZT) 0.05 400 - 1 - -2  
Sample 8 (AZT)  0.05 
sonicated  
93 - 0.98 - 6  
Sample 9 (AZT) 0.1 839 - 1 - -3.5  
Sample 10 (AZT)  0.2 501.2 - 0.917 - -2.91 - 
Sample 11 (AZT)  0.5 
sonicated  
117.1 - 0.528 - 5.61 - 
Sample 12 (AZT) 0.5 1890 - 1 - -8  
 
Ethyl acetate was preferred over chloroform because it is less toxic than the latter. 
Further experimentation was carried out with ethyl acetate as the organic solvent. 
Changes were made to the concentration of gelatin in this exercise. Some gelatin 
samples were sonicated to aid with solubility before use because it was apparent that 
the size of the formulated NPs were affected by concentration and effects of sonication 
as seen in Table A1.3. When gelatin was sonicated before use, the nanoparticle sizes 
were of a lower value compared to the same concentration when gelatin was not 
sonicated. The concentration of gelatin was also varied and its effect on particle size 
investigated. 
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D. Organic solvent: ethyl acetate/acetone ratio 4:1 
Samples in this category were homogenized before sonication, unlike the samples 
previously prepared which were homogenized after sonication, to determine which 
sequence will yield the smallest particles sizes. The concentration of gelatin was kept 
constant at 0.05% w/v and the gelatin stock solution was sonicated before use. An 
exception was sample 3 which was not sonicated, this was to determine if there would 
be any difference in particle size, PDI and zeta potential when there is sonication and 
when there is no sonication (Table A1.3). 
Table A1.3: Particle size, polydispersity index and zeta potential of formulated 
nanoparticles obtained when samples were homogenized before sonication. 
Solvent  
Ethyl acetate / 
Acetone (4:1)  
Particle size (nm)  Polydispersity index  Zeta potential  
Before 
wash  
After 
wash  
Before 
wash  
After wash  Before 
wash  
After 
wash 
Sample 1 99.66 360 0.412 3.12 3.12 -8.63 
Sample 2 126.9 278 0.385 0.365 2.85 -9.05 
Sample 3* 1895 1688 1 1 - - 
*samples not sonicated 
E. Reduction of sample size  
Organic solvent: ethyl acetate/acetone ratio 4:1 
The sample was prepared using the general method earlier reported with the 
exception that the w/o/w double emulsion prepared was not poured into 200 ml of 
water containing 0.05% gelatin but instead was directly transferred to the rotavapor 
for solvent evaporation at 400 rpm for 4 hrs. This step did not yield much difference in 
the particle size because the NPs were still not within the desired particle size range 
of 100-200 nm (Table A1.4). 
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Table A1.4: Particle size, polydispersity index and zeta potential of formulated 
nanoparticles obtained when sample size was reduced. 
Solvent  Particle size (nm)  Polydispersity index  Zeta potential  
Before 
wash  
After 
wash  
Before 
wash  
After wash  Before 
wash  
After 
wash 
Ethyl acetate / 
Acetone (4:1) 
1237 - 1 - - - 
 
F. Organic solvent less than 10ml i.e. ethyl acetate and acetone (4:1) 
The emulsion was prepared with the general method reported above, with slight 
modification in the total volume of organic solvent (ethyl acetate and acetone) 
used. Instead of using a total volume of 10 ml, we tested 5 ml and 6 ml of the 
organic solvent in the same combination and ratio as above. The organic solvents 
were used individually as well to dissolve the polymer. A portion of the polymer 
precipitated during the process (Figure A1.2); and the sample was therefore 
discarded. 
 
Figure A1.2: Precipitation of sample (AZT and TDF) when less than 10ml of the 
organic solvent (ethyl acetate and acetone) was used. 
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Appendix B 
Reduction of total sample size from 251 ml to 91 ml using d-α-tocopheryl 
polyethylene glycol 1000 succinate (TPGS) and tween 80. 
The general method previously described (appendix A) produced a total sample 
volume of 251 ml and this was very cumbersome and time consuming to centrifuge. 
In addition, some of the sample was lost during this process. There was thus a 
need to reduce the total sample size. The gelatin which was used as a surfactant 
affected the particle sizes of the NPs hence the change to TPGS. The general 
method below was used to accommodate these changes. 
Method  
1) 100 mg of polymer was weighed and dissolved in 10 ml of a mixture of 4:1 ethyl 
acetate/acetone and vortexed to ensure that it was completely dissolved. 
2) 5 mg of the API was dissolved in (1) ml of water containing 0.2% w/v tween 80. 
3) (2) was homogenized in 1 at a speed of 5000 rpm for 2 min and sonicated at 
87 kHz for 30 seconds under an ice bath to produce the primary emulsion. 
4) (3) was added dropwise into 40 ml of external water containing 0.12% TPGS 
and homogenized for 3 min at a speed of 12000 rpm. The mixture was then 
sonicated at 87 kHz for 2 min. 
5) The w/o/w double emulsion was poured gradually into a beaker containing 40 
ml of 0.2% tween 80 while stirring with a magnetic stirrer at 800 rpm.  
6) The solution was evaporated using the rotavapor at a speed of 400 rpm and 
temperature between 30-35 degrees for 6 hrs to completely evaporate the 
organic solvents. 
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7) The nanoparticles where spun at a speed of 16500 rpm for 60 min to collect the 
pellets which settled at the bottom. 
8) The pellets where washed three times with distilled water. 
G. Sample preparation without TPGS  
The sample was prepared using the method described above, however only with 
tween 80 (and no TPGS) as follows: The TPGS in step 4 was replaced with tween 80 
thus in the final stage no surfactant was used. However, following centrifugation at a 
temperature of 4˚C and speed of 16500 rpm for 30 mins, the nanoparticles could not 
be collected. A possible reason for this might have been that the particle sizes were 
too small, and a higher centrifugation speed was needed for the nanoparticles formed 
to settle and  be collected from the sample. This sample was rejected (Table B1.1). 
Table B1.1: Particle size, polydispersity index and zeta potential of formulated 
nanoparticles obtained when sample size was reduced and preparation was without 
TPGS.  
Solvent  Particle size (nm)  Polydispersity index  Zeta potential  
Before 
wash  
After 
wash  
Before 
wash  
After 
wash  
Before 
wash  
After 
wash 
Ethyl acetate / 
Acetone (4:1) 
89.92 - 0.232 - -4.94 - 
 
H. Sample preparation with TPGS  
The sample was prepared as described previously by the general method in appendix 
B. Formulation data from this activity are presented in Table B1.2. Following 
preparation, the samples were spun at a speed of 26000 rpm for 30 mins. In the 
process, the Eppendorf tubes containing the samples were broken, leading to loss of 
samples. A possible reason proffered for this was the centrifuge speed, which may 
have been too high for the tubes used.  
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Table B1.2: Particle size, polydispersity index and zeta potential of formulated 
nanoparticles obtained when sample size was reduced and preparation was with 
TPGS.  
Solvent  Particle size (nm)  Polydispersity index  Zeta potential  
Before 
wash  
After 
wash  
Before 
wash  
After wash  Before 
wash  
After 
wash 
Ethyl acetate / 
Acetone (4:1) 
107.7 - 0.161 - -5.71 - 
 
I. Sample prepared with TPGS  
The samples prepared in section H above confirmed the method to be used. The 
prepared sample was collected by centrifuging at a lower speed of 16500 rpm for one 
hour. The collected pellets were washed and freeze-dried. Data obtained from this 
activity is presented in Table B1.3. 
 Table B1.3: Particle size, polydispersity index and zeta potential of formulated 
nanoparticles obtained when sample size was reduced, reduced collection speed 
(16500) and preparation was with TPGS. 
Solvent  
Ethyl acetate / 
Acetone (4:1) 
Particle size (nm)  Polydispersity index  Zeta potential  
Before 
wash  
After 
wash  
Before 
wash  
After 
wash  
Before 
wash  
After 
wash 
Sample 1 111.5 156.9 0.128 0.317 -10.9 -16.6 
Sample 2 117.3 153.2 0.160 0.303 -8.84 -19.1 
 
Appendix C : Validation of UV-VIS assay method for tenofovir disoproxil 
fumarate and zidovudine in PBS at pH 1.2 and pH 7.4. 
The tables presented by appendix C are computational data used for a standard 
callibration curve for both AZT and TDF. It also provides data used to prove the 
accuracy and precission of the of HPLC-DAD and UV-spectrometry method used for 
the prediction of TDF and AZT.  
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Table C1.1: Calibration plot of TDF at pH 7.4 and pH 1.2 (HPLC-DAD analyses). 
Concentration 
(μg/ml) 
Mean Absorbance %RSD 
 pH 7.4 pH 1.2 pH 7.4 pH 1.2 
0.02 34.15 71.40 0.42 1.2 
0.04 68.27 143.55 2.06 2.0 
0.06 102.31 213.44 0.28 3.0 
0.08 135.92 284.22 0.86 1.7 
0.10 168.55 371.71 0.39 3.0 
0.12 201.07 420.0 0.96 0.5 
 
Table C1.2: Calibration plot of TDF at pH 7.4 and pH 1.2 (UV-spectrometry 
analyses)  
Concentration 
(μg/ml) 
Mean Absorbance %RSD 
 pH 7.4 pH 1.2 pH 7.4 pH 1.2 
2 0.0295 0.0696 0.71 4.9 
4 0.0817 0.1358 1.22 0.13 
6 0.1306 0.1745 0.27 0.10 
8 0.1630 0.2018 0.18 0.05 
10 0.1927 0.2337 0.05 0.04 
12 0.2424 0.2794 0.04 0.14 
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Table C1.3: Selected FTIR data for TDF, PLGA 50:50, PLGA 85:15, TDF-PLGA 
50:50 physical mixture, and TDF-PLGA 85:15 physical mixture 
Analyzed 
sample  
Experiment
al frequency 
bands (cm-1) 
Standard 
frequency 
bands (cm-1) 
Associated functional groups 
from IR bands  
TDF 3459.12 3400-3500 Medium N-H stretching  
2981.38 2300-3300 Strong broad O-H stretching  
2814.22 2850 - 2810 Medium –OCH3 stretching  
2018.44 2140 - 1990 Strong and broad –N=C=S stretching  
1752.31 1800 - 1750 Strong C=0 stretching  
1671.87 1685 - 1665 
PLGA 50:50  2950.52 2960 - 2850 Chelated O-H stretching bridge  
1750.32 1800 – 1750  C=O stretching of the carbonyl group 
PLGA 85:15 2996.25 3000 - 2500  Chelated O-H stretching bridge 
1745.64 1790 - 1740 Strong C=O stretching of the 
carbonyl group 
TDF-PLGA 
50:50 
physical 
mixture  
2993.81 3000 - 2500  Chelated O-H stretching bridge 
1750.07 1790 - 1740 Strong C=O stretching of the 
carbonyl group 
TDF-PLGA 
85:15 
physical 
mixture  
2985.88 3000 - 2500  Chelated O-H stretching bridge 
1754.32 1790 - 1740 Strong C=O stretching of the 
carbonyl group 
1674.85 1685 - 1665 Strong C=0 stretching 
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Table C1.4: Thermogravimetric analysis of data for TDF, polymers and TDF-polymer 
physical mixture 
Sample  Mass loss 
events  
Tonset ± 1 (°C)  Tdeg.max. 
±1 (°C) 
Tendset ± 1 (°C) Total mass 
loss (%) 
PLGA 50:50 1st  236 322 324 98  
2nd  335 376 378 
PLGA 85:15 1st  221 311 313 100 
2nd  318 389 390 
TDF-PLGA 
50:50 
 215 399 400 93 
TDF-PLGA 
85:15 
 217 396 397 98 
TDF  1st  135 199 201 87 
2nd  203 275 276 
 
Table C1.5: Thermal properties of TDF-PLGA loaded nanoparticles 
Drug polymer 
combination 
Mass loss 
events 
Tonset 
(°C) 
Tdeg.max. 
(°C) 
Tendset 
(°C) 
Total mass 
loss (%) 
TDF-PLGA 50:50 
loaded 
1st 206 355 356 93 
2nd 356 424 425 
TDF-PLGA 85:15 
loaded 
1st 234 340 341 91 
2nd 343 396 397 
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Table C1.6: Calibration plot of AZT at pH 7.4 and pH 1.2, (HPLC-DAD analyses) 
Concentration (μg/ml) Mean Absorbance %RSD 
 pH 7.4 pH 1.2 pH 7.4 pH 1.2 
0.02 165.83 124.97 0.72 0.85 
0.04 330.59 249.14 0.17 0.99 
0.06 495.44 391.12 0.28 0.19 
0.08 656.09 494.27 0.02 0.4 
0.10 824.70 614.31 0.13 0.32 
0.12 976.90 745.93 0.2 0.2 
 
Table C1.7: Calibration plot of AZT at pH 7.4 and pH 1.2 (UV-spectrometry analyses) 
Concentration 
(μg/ml) 
Mean Absorbance %RSD 
 pH 7.4 pH 1.2 pH 7.4 pH 1.2 
2 0.0869 0.1100 0.24 0.18 
4 0.1539 0.1625 0.10 0.06 
6 0.2231 0.2539 0.09 0.37 
8 0.2927 0.3248 0.07 0.06 
10 0.3666 0.3993 0.27 0.09 
12 0.428 0.4649 
 
0.19 0.08 
 
Table C1.8: Thermal properties of AZT, polymers and AZT-polymer physical mixture 
Sample  Mass loss 
events  
Tonset 
(°C) 
Tdeg.max. (°C) Tendset (°C) Total mass 
loss (%) 
AZT-PLGA 50:50 1st  218 353 355 94 
2nd  357 398 399 
AZT-PLGA 85:15  220 386 387 97 
AZT  1st  172 247 257 76 
2nd  249 317 318 
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Table C1.9: Selected FTIR data for AZT-PLGA 50:50 loaded nanoparticles, AZT-
PLGA 85:15 loaded nanoparticles, AZT-PLGA 50:50 physical mixture, and AZT-
PLGA 85:15 physical mixture 
Compound  Experimental 
frequency 
bands (cm-1) 
Standard 
frequency 
bands (cm-1) 
Associated functional 
groups from IR bands  
AZT-PLGA 50:50 
loaded 
2948.36 3000 - 2500 Chelated O-H stretching bridge 
1748.67 1770 - 1710 Strong C=O stretching 
AZT-PLGA 85:15 
loaded 
2995.93 2960 - 2850 Strong C-H bending  
2945.50 3000 - 2500 Chelated O-H stretching bridge 
1748.02 1770 - 1710 Strong C=O stretching 
AZT-PLGA 50:50 
physical mixture  
3461.12 3500 - 3300 Medium N-H stretching bands 
3023.15 3000 - 2500 Chelated O-H stretching bridge 
2814.57 3200 - 2500 O-H stretching 
2082.39 2160-2120 Strong N=N=N stretching 
1751.54 1770 - 1710 Strong C=O stretching 
 1679.98 1685-1666 Strong C=O stretching 
AZT-PLGA 85:15 
physical mixture  
3460.60 3500 - 3300 Medium N-H stretching bands 
3023.04 3000 - 2500 Chelated O-H stretching bridge 
2082.15 2160-2120 Strong N=N=N stretching 
1750.91 1770 - 1710 Strong C=O stretching 
1677.09 1685-1666 Strong C=O stretching 
 
Table C1.10: Thermal properties of AZT-PLGA loaded nanoparticles 
Drug polymer combination Mass loss 
events 
Tonset 
(°C) 
Tdeg.max. 
(°C) 
Tendset (°C) Total mass 
loss (%) 
AZT-PLGA 50:50 loaded 1st  225 414 415 100 
AZT-PLGA 85:15 loaded 1st  234 334 335 93  
2nd  335 402 403 
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